

Stereotactic ablative radiotherapy versus standard of care  
with oligometastatic cancers (SABR-COMET): a random

Lancet, The

393, 2051-2058

DOI: [10.1016/s0140-6736\(18\)32487-5](https://doi.org/10.1016/s0140-6736(18)32487-5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5. <i>BMC Cancer</i> , 2018, 18, 954.	1.1	16
2	Advanced radiotherapy for metastatic diseaseâ€”a major stride or a futile effort?. <i>Annals of Palliative Medicine</i> , 2019, 8, 337-351.	0.5	10
3	Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Nonâ€”Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2019, 2, e199702.	2.8	34
4	Translational and basic science opportunities in palliative care and radiation oncology. <i>Annals of Palliative Medicine</i> , 2019, 8, 326-336.	0.5	0
5	Stereotactic ablative radiotherapy for the comprehensive treatment of 4â€”10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. <i>BMC Cancer</i> , 2019, 19, 816.	1.1	165
6	Radiotherapy and Immunotherapyâ€”Shining Further Together. <i>JAMA Oncology</i> , 2019, 5, 1291.	3.4	8
7	Stereotactic Body Radiotherapy in Metastatic Disease: The Known Unknowns and the Unknown Unknowns. <i>Clinical Oncology</i> , 2019, 31, 813-814.	0.6	1
8	The Yin and Yang of Cytoreductive SBRT in Oligometastases and Beyond. <i>Frontiers in Oncology</i> , 2019, 9, 706.	1.3	8
9	Integration of radiotherapy and immunotherapy for treatment of oligometastases. <i>Lancet Oncology</i> , The, 2019, 20, e434-e442.	5.1	98
10	Rational combinations of immunotherapy with radiotherapy in ovarian cancer. <i>Lancet Oncology</i> , The, 2019, 20, e417-e433.	5.1	89
11	Differential Relapse Patterns for Non-small Cell Lung Cancer Subtypes Adenocarcinoma and Squamous Cell Carcinoma: Implications for Radiation Oncology. <i>Clinical Oncology</i> , 2019, 31, 711-719.	0.6	14
12	The emerging role of PET-CT scan after radical prostatectomy: still a long way to go. <i>Lancet Oncology</i> , The, 2019, 20, 1193-1195.	5.1	4
13	An image-based deep learning framework for individualising radiotherapy dose: a retrospective analysis of outcome prediction. <i>The Lancet Digital Health</i> , 2019, 1, e136-e147.	5.9	148
14	Salvage Curative-Intent Reirradiation Stereotactic Body Radiation Therapy for Isolated Pelvic and/or Paraortic Recurrences of Gynecologic Malignancies. <i>Practical Radiation Oncology</i> , 2019, 9, 418-425.	1.1	8
17	Using Stereotactic Body Radiotherapy to Overcome the Radioresistant Reputation of Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2019, 2, 524-525.	2.6	1
18	Recommendations for Single-Fraction Radiation Therapy and Stereotactic Body Radiation Therapy in Palliative Treatment of Bone Metastases: Aâ€”Statewide Practice Patterns Survey. <i>Practical Radiation Oncology</i> , 2019, 9, e541-e548.	1.1	10
19	Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 961.	1.3	12
20	Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. <i>Radiation Oncology</i> , 2019, 14, 177.	1.2	13

#	ARTICLE	IF	CITATIONS
21	Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1219.	1.3	27
22	Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach?. <i>Frontiers in Medicine</i> , 2019, 6, 244.	1.2	31
23	Long-term survival in patients with metastatic head and neck squamous cell carcinoma treated with metastasis-directed therapy. <i>British Journal of Cancer</i> , 2019, 121, 897-903.	2.9	32
25	&lt;p&gt;Physician And Patient Barriers To Radiotherapy Service Access: Treatment Referral Implications&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 8829-8833.	0.9	15
26	Stereotactic body radiotherapy in patients with multiple lung tumors: a focus on lung dosimetric constraints. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 959-969.	1.1	7
27	Randomized phase II trial reporting overall survival advantage by adding local consolidative therapy to systemic therapy for oligometastatic non-small cell lung cancer: another step forward on the long road of evidence-based medicine for oligometastatic disease. <i>Journal of Thoracic Disease</i> , 2019, 11, S1869-S1873.	0.6	2
28	Local consolidative therapy in metastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, S1909-S1912.	0.6	1
29	EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. <i>European Journal of Cancer</i> , 2019, 122, 109-114.	1.3	33
30	Feasibility and preliminary clinical results of linac-based Stereotactic Body Radiotherapy for spinal metastases using a dedicated contouring and planning system. <i>Radiation Oncology</i> , 2019, 14, 184.	1.2	17
33	Multiparametric magnetic resonance imaging-guided salvage radiotherapy in prostate cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2019, 24, 472-480.	0.3	2
34	A national survey on technology and quality assurance for stereotactic body radiation therapy. <i>Physica Medica</i> , 2019, 65, 6-14.	0.4	10
35	Stereotactic body radiation therapy versus multi-fraction radiation therapy for bone metastases. <i>Annals of Palliative Medicine</i> , 2019, 8, 360-363.	0.5	1
36	Radioablation +/âˆ¬ hormone therapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159). <i>BMC Cancer</i> , 2019, 19, 903.	1.1	9
38	Combining immunotherapy and radiotherapy for the STAR treatment. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 666-667.	12.5	21
39	The evolving role of radiotherapy in non-small cell lung cancer. <i>British Journal of Radiology</i> , 2019, 92, 20190524.	1.0	88
40	Evolution of treatment strategies for oligometastatic NSCLC patients â€“ A systematic review of the literature. <i>Cancer Treatment Reviews</i> , 2019, 80, 101892.	3.4	45
41	Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 943-947.	0.4	46
42	Changing equipoise in the landscape of radiation for oligometastatic lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S184-S191.	1.3	2

#	ARTICLE	IF	CITATIONS
43	Current landscape of palliative radiotherapy for non-small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S192-S201.	1.3	34
44	Combining Radiation Therapy with Immune Checkpoint Blockade in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2019, 11, 203-216.	0.5	2
46	Hypofractionated Image-Guided Radiation Therapy With Simultaneous-Integrated Boost Technique for Limited Metastases: A Multi-Institutional Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 469.	1.3	4
47	The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?. <i>Clinical Oncology</i> , 2019, 31, 824-833.	0.6	66
48	Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Nodules: A Single Institution Series. <i>Frontiers in Oncology</i> , 2019, 9, 334.	1.3	7
49	A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead?. <i>Frontiers in Oncology</i> , 2019, 9, 543.	1.3	54
50	Survival benefit of radiotherapy after surgery in de novo stage IV breast cancer: a population-based propensity-score matched analysis. <i>Scientific Reports</i> , 2019, 9, 8527.	1.6	19
51	Integrated molecular and clinical staging defines the spectrum of metastatic cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 581-588.	12.5	52
52	Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview. <i>Frontiers in Oncology</i> , 2019, 9, 337.	1.3	74
53	The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado?. <i>Clinical Oncology</i> , 2019, 31, 432-443.	0.6	48
54	SABR improves outcomes. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 402-402.	12.5	5
55	SABR-COMET: harbinger of a new cancer treatment paradigm. <i>Lancet, The</i> , 2019, 393, 2013-2014.	6.3	14
56	Les cancers bronchiques non À petites cellules oligomÃ©tastatiques: dÃ©finition et prise en charge. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, 290-297.	0.0	0
58	The utilization patterns and comparative effectiveness of systemic therapy with high-dose thoracic radiotherapy or low-dose thoracic radiotherapy versus systemic therapy alone in newly diagnosed metastatic non-small cell lung cancer patients. <i>Journal of Radiation Oncology</i> , 2019, 8, 425-438.	0.7	0
59	Paradigm shift in local consolidative therapy for oligometastatic non-small cell lung cancer: a meta-analysis. <i>Annals of Translational Medicine</i> , 2019, 7, S320-S320.	0.7	0
60	Best practices and guidelines for the management of thymic epithelial tumors. <i>Mediastinum</i> , 2019, 3, 32-32.	0.6	1
61	Critical review of multidisciplinary non-surgical local interventional ablation techniques in primary or secondary liver malignancies. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 589-600.	0.4	10
62	Improved clinical outcomes following additional aggressive local consolidative therapy to systemic therapy for oligometastasis from lung cancer: where do we stand between â€œrealityâ€œ and â€œillusionâ€œ?. <i>Journal of Thoracic Disease</i> , 2019, 11, E217-E220.	0.6	1

#	ARTICLE	IF	CITATIONS
63	The PEMBRO-RT phase II randomized trial and the evolution of therapy for metastatic non-small cell lung cancer: a historical perspective. <i>Annals of Translational Medicine</i> , 2019, 7, S294-S294.	0.7	0
64	Surveillance imaging for non-small cell lung cancer: mounting evidence that less is more. <i>Translational Lung Cancer Research</i> , 2019, 8, S343-S346.	1.3	2
65	Local consolidative therapy for oligometastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 5649-5651.	0.6	2
66	Accelerating the development of therapeutic strategy for oligometastasis. <i>Journal of Thoracic Disease</i> , 2019, 11, 5670-5673.	0.6	1
67	Beyond the scalpel â€“ mortality after liver surgery in patients with liver metastases â€“ time to rethink the indications. <i>British Journal of Surgery</i> , 2019, 107, 149-149.	0.1	0
68	&lt;p&gt;Single-Fraction Radiotherapy (SFRT) For Bone Metastases: Patient Selection And Perspectives&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 9397-9408.	0.9	10
69	Oligometastatic Disease in NSCLC â€” Not Just Wishful Thinking?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2042-2045.	0.5	3
70	Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients. <i>Respiratory Research</i> , 2019, 20, 263.	1.4	5
71	Pulmonary Metastasectomy versus Continued Active Monitoring in Colorectal Cancer (PulMiCC): a multicentre randomised clinical trial. <i>Trials</i> , 2019, 20, 718.	0.7	148
72	Abscopal effect in lung cancer: three case reports and a concise review. <i>Immunotherapy</i> , 2019, 11, 1445-1461.	1.0	37
73	Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matter. <i>Radiotherapy and Oncology</i> , 2020, 142, 236-245.	0.3	27
74	Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Nonâ€“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 37-46.e7.	1.1	44
75	Predicting Survival for Patients With Metastatic Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 52-60.	0.4	18
76	Cytoreductive treatment strategies for de novo metastatic prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 168-182.	12.5	36
77	Stereotactic MR-guided adaptive radiation therapy for peripheral lung tumors. <i>Radiotherapy and Oncology</i> , 2020, 144, 46-52.	0.3	64
78	Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases. <i>JAMA Oncology</i> , 2020, 6, 567.	3.4	64
79	Clinical and practical applications of radiation therapy: when should radiation therapy be considered for my patient?. <i>Medicine</i> , 2020, 48, 84-89.	0.2	1
80	A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. <i>Oncologist</i> , 2020, 25, e311-e320.	1.9	56

#	ARTICLE	IF	CITATIONS
81	Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. <i>Lancet Oncology</i> , The, 2020, 21, e18-e28.	5.1	588
82	High versus low dose Stereotactic Body Radiation Therapy for hepatic metastases. <i>Clinical and Translational Radiation Oncology</i> , 2020, 20, 45-50.	0.9	21
83	Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non-“Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: Brief Report. <i>Clinical Lung Cancer</i> , 2020, 21, e57-e60.	1.1	5
84	A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 546-555.	0.4	42
85	Stereotactic Body Radiation Therapy for Extracranial Oligometastatic Non-“small-cell Lung Cancer: A Systematic Review. <i>Clinical Lung Cancer</i> , 2020, 21, 95-105.e1.	1.1	10
86	Appropriate endpoints for stereotactic body radiotherapy for bone metastasis: Classification into five treatment groups. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 150-153.	0.3	13
87	Curative management of a cardiac metastasis from lung cancer revealed by an electrical storm. <i>Clinical and Translational Radiation Oncology</i> , 2020, 21, 62-65.	0.9	5
88	Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). <i>Clinical and Translational Radiation Oncology</i> , 2020, 21, 32-35.	0.9	6
89	Novel Dose Escalation Approaches for Stereotactic Body Radiotherapy to Adrenal Oligometastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 107-114.	0.6	11
90	Online Prostate-Specific Membrane Antigen and Positron Emission Tomography-“Guided Radiation Therapy for Oligometastatic Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2020, 5, 260-268.	0.6	13
92	Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 753-766.	0.8	100
93	The Evolution (and Future) of Stereotactic Body Radiotherapy in the Treatment of Oligometastatic Disease. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 307-320.	0.9	11
94	PSMA PET-“CT redefines nonmetastatic castration-resistant prostate cancer. <i>Nature Reviews Urology</i> , 2020, 17, 133-134.	1.9	5
95	Combination of Local Ablative Therapy and Continuation of Immune Checkpoint Inhibitor (ICI) Therapy Provides Durable Treatment Response Past Oligometastatic Progression in NSCLC: A Case Report. <i>Case Reports in Oncology</i> , 2020, 12, 866-871.	0.3	7
96	Palliative Radiotherapy. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 253-277.	0.9	5
97	Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial. <i>Breast</i> , 2020, 49, 55-62.	0.9	49
98	Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with -“curative-“intent. <i>Lung Cancer</i> , 2020, 141, 1-8.	0.9	17
99	Salvage Therapies After 18F-Fluciclovine Detected Prostate Cancer Recurrences. <i>Clinical Nuclear Medicine</i> , 2020, 45, 668-671.	0.7	3

#	ARTICLE	IF	CITATIONS
100	Role of Locoregional Treatment in De Novo Stage IV Breast Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492094244.	0.6	13
101	SABR-BRIDGE: Stereotactic Ablative Radiotherapy Before Resection to Avoid Delay for Early-Stage Lung Cancer or Oligometastases During the COVID-19 Pandemic. <i>Frontiers in Oncology</i> , 2020, 10, 580189.	1.3	19
102	Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100216.	0.7	6
103	Replacing 30 Gy in 10 fractions with stereotactic body radiation therapy for bone metastases: A large multi-site single institution experience 2016–2018. <i>Clinical and Translational Radiation Oncology</i> , 2020, 25, 75-80.	0.9	9
104	KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. <i>Cancer Discovery</i> , 2020, 10, 1826-1841.	7.7	93
105	Radiation therapy for oligometastatic bone disease in breast cancer. <i>Translational Cancer Research</i> , 2020, 9, 5096-5101.	0.4	3
106	Image-guided Radiotherapy to Manage Respiratory Motion: Lung and Liver. <i>Clinical Oncology</i> , 2020, 32, 792-804.	0.6	33
108	Effect of Surgery at Primary and Metastatic Sites in Patients With Stage IV Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 170-180.	1.1	9
109	Full automation of spinal stereotactic radiosurgery and stereotactic body radiation therapy treatment planning using Varian Eclipse scripting. <i>Journal of Applied Clinical Medical Physics</i> , 2020, 21, 122-131.	0.8	5
110	Radiotherapy for primary tumor in lung cancer with synchronous metastases: Overview from the past and proposal for the future. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2020, 24, 554-558.	0.6	1
111	Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2020, 139, 81-89.	1.3	17
112	Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers. <i>Gynecologic Oncology</i> , 2020, 159, 611-617.	0.6	14
113	Pulmonary toxicity in patients treated with immune checkpoint inhibitors and radiation. <i>Annals of Oncology</i> , 2020, 31, 1597-1598.	0.6	1
114	Is repeated pulmonary metastasectomy justified?. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 675-682.	1.7	14
115	Combined Radiotherapy and New Systemic Therapies—Have We Moved Beyond Palliation?. <i>Clinical Oncology</i> , 2020, 32, 758-765.	0.6	6
116	The Role of Definitive Radiation and Surgery in Metastatic Esophageal Cancer: An NCDB Investigation. <i>Annals of Thoracic Surgery</i> , 2021, 112, 459-466.	0.7	4
117	The Reintroduction of Radiotherapy Into the Integrated Management of Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 448-459.	1.0	1
118	Repeat Thoracic Stereotactic Body Radiation Therapy (SBRT) for Non-small Cell Lung Cancer: Long-Term Outcomes, Toxicity, and Dosimetric Considerations. <i>Advances in Radiation Oncology</i> , 2020, 5, 984-993.	0.6	9

#	ARTICLE	IF	CITATIONS
119	Survival Outcomes and Prognostic Analysis Following Greater Cytoreductive Radiotherapy in Patients With Metastatic Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 549220.	1.3	3
120	Trials of locoregional therapies inspired by SABR-COMET. <i>Lancet, The</i> , 2020, 396, 956-957.	6.3	5
121	Clinical Trialism and the Bedrock of Hope. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 876-878.	0.4	3
122	Commentary on Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 927-929.	0.4	0
123	Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: A systematic review. <i>Gynecologic Oncology</i> , 2020, 159, 573-580.	0.6	20
125	Reply to VÃ©rane Achard, Alan Dal Pra, and Thomas Zilliâ€™s Letter to the Editor re: Carlo A. Bravi, Nicola Fossati, Giorgio Gandaglia, et al. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. <i>Eur Urol</i> 2020;78:661â€“9. <i>European Urology</i> , 2020, 78, e223-e224.	0.9	4
126	Curing Metastatic Disease With Ablative Radiation Therapy: Separating Truth From Wish. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 433-436.	0.4	3
127	Role of high-dose salvage radiotherapy for oligometastases of the localised abdominal/pelvic lymph nodes: a retrospective study. <i>BMC Cancer</i> , 2020, 20, 540.	1.1	15
128	Combinatorial Immunotherapies for Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1875.	1.7	19
129	Clinical Outcomes of Combined Prostate- and Metastasis-Directed Radiation Therapy for the Treatment of De Novo Oligometastatic Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2020, 5, 1213-1224.	0.6	7
130	Consolidative Radiotherapy in Oligometastatic Lung Cancer: Patient Selection With a Prediction Nomogram. <i>Clinical Lung Cancer</i> , 2020, 21, e622-e632.	1.1	9
131	Mind Over Magnets â€” How Magnetic Particle Imaging is Changing the Way We Think About the Future of Neuroscience. <i>Neuroscience</i> , 2021, 474, 100-109.	1.1	7
132	Long-term outcome after combined kyphoplasty and intraoperative radiotherapy (Kypho-IORT) for vertebral tumors. <i>Radiation Oncology</i> , 2020, 15, 263.	1.2	9
133	&lt;p&gt;Hypofractionated Radiotherapy for 35 Patients with Adrenal Metastases: A Single-Institution Experience&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 11563-11571.	0.9	2
134	Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 576643.	1.3	13
135	Use of stereotactic body radiotherapy in gynecologic cancers: Local control with systemic treatment implications. <i>Gynecologic Oncology</i> , 2020, 159, 599-600.	0.6	1
137	Radiation Therapy in Adult Soft Tissue Sarcomaâ€™ Current Knowledge and Future Directions: A Review and Expert Opinion. <i>Cancers</i> , 2020, 12, 3242.	1.7	14
138	Hsa-miR-375/RASD1 Signaling May Predict Local Control in Early Breast Cancer. <i>Genes</i> , 2020, 11, 1404.	1.0	7



#	ARTICLE	IF	CITATIONS
139	The Impact of 18F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2020, 5, 1364-1369.	0.6	5
140	<i>Advances in Radiobiology of Stereotactic Ablative Radiotherapy. Frontiers in Oncology</i> , 2020, 10, 1165.	1.3	34
141	Radiation therapy on primary tumour of synchronous metastatic head and neck squamous cell carcinomas. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2020, 24, 559-566.	0.6	6
142	Metastasis-directed Therapy (SBRT) Guided by PET-CT 18F-CHOLINE Versus PET-CT 68Ga-PSMA in Castration-sensitive Oligorecurrent Prostate Cancer: A Comparative Analysis of Effectiveness. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 230-236.	0.9	53
143	Stereotactic Body Radiation Therapy (SBRT) in Pelvic Lymph Node Oligometastases. <i>Cancer Investigation</i> , 2020, 38, 599-607.	0.6	2
144	The Importance of Locoregional Therapy in Metastatic Nasopharyngeal Cancer. <i>JAMA Oncology</i> , 2020, 6, 1353.	3.4	4
145	Radiotherapy in women with epithelial ovarian cancer: historical role, current advances, and indications. <i>Chinese Clinical Oncology</i> , 2020, 9, 49-49.	0.4	5
146	SABR for metastasis-directed therapy “ what we’ve learned and what’s to come. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 593-594.	12.5	1
147	SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. <i>Journal of Hematology and Oncology</i> , 2020, 13, 105.	6.9	73
148	Safety and Efficacy of Stereotactic Body Radiation Therapy for Locoregional Recurrences After Prior Chemoradiation for Advanced Esophageal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1311.	1.3	2
150	Adrenal SBRT: a multi-institutional review of treatment outcomes and toxicity. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 585-592.	1.7	7
151	Spine and Non-spine Bone Metastases “ Current Controversies and Future Direction. <i>Clinical Oncology</i> , 2020, 32, 728-744.	0.6	10
152	Stereotactic Body Radiation Therapy of Adrenal Metastases: A Pooled Meta-Analysis and Systematic Review of 39 Studies with 1006 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 48-61.	0.4	55
153	Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1345.	3.4	137
154	Stereotactic Radiosurgery and Stereotactic Body Radiotherapy in the Management of Oligometastatic Disease. <i>Clinical Oncology</i> , 2020, 32, 713-727.	0.6	30
155	Radiation Therapy and the In Situ Vaccination Approach. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 891-898.	0.4	46
156	Stereotactic radiation therapy for breast cancer in the elderly. <i>Translational Cancer Research</i> , 2020, 9, S86-S96.	0.4	2
157	Radiation oncology should be a partner to medical oncology in end-of-life care. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 155-156.	0.3	0

#	ARTICLE	IF	CITATIONS
158	Therapeutic Concepts for Oligometastatic Gastrointestinal Tumours. <i>Visceral Medicine</i> , 2020, 36, 359-363.	0.5	2
159	Characteristics of Patients and Treatment Recommendations from a Multidisciplinary Spinal Tumor Program. <i>Palliative Medicine Reports</i> , 2020, 1, 143-148.	0.4	11
160	Current topics in radiotherapy for genitourinary cancers: Consensus statements of the Genitourinary Radiation Oncologists of Canada. <i>Canadian Urological Association Journal</i> , 2020, 14, E588-E593.	0.3	4
161	Analyses of the local control of pulmonary Oligometastases after stereotactic body radiotherapy and the impact of local control on survival. <i>BMC Cancer</i> , 2020, 20, 997.	1.1	19
162	A single-institutional experience with low dose stereotactic body radiation therapy for liver metastases. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 987-993.	0.3	2
163	A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer. <i>Radiotherapy and Oncology</i> , 2020, 152, 80-88.	0.3	9
164	Outcomes and the Role of Primary Histology Following LINAC-based Stereotactic Radiation for Sarcoma Brain Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 356-361.	0.6	5
165	Pediatric and young adult renal cell carcinoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28675.	0.8	14
166	Patterns of Lymph Node Failure in Patients With Recurrent Prostate Cancer Postradical Prostatectomy and Implications for Salvage Therapies. <i>Advances in Radiation Oncology</i> , 2020, 5, 1126-1140.	0.6	9
168	Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 151, 280-286.	0.3	11
169	Stereotactic Body Radiation Therapy in Oligometastatic Uterine Cancer: Clinical Outcomes and Toxicity. <i>Cancer Investigation</i> , 2020, 38, 522-530.	0.6	8
170	Patterns of disease progression to checkpoint inhibitor immunotherapy in patients with stage IV non-small cell lung cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 866-872.	0.9	3
171	Single-Fraction Stereotactic Body Radiation Therapy: A Paradigm During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond?. <i>Advances in Radiation Oncology</i> , 2020, 5, 761-773.	0.6	28
172	Pulmonary oligometastases treated by stereotactic body radiation therapy (SBRT): a single institution's experience. <i>Translational Lung Cancer Research</i> , 2020, 9, 1496-1506.	1.3	5
173	Stereotactic ablative radiotherapy for bone metastasis of gastrointestinal stromal tumor: Case report and review of the literature. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 331-335.	0.3	3
174	Outcome and toxicity of hypofractionated image-guided SABR for spinal oligometastases. <i>Clinical and Translational Radiation Oncology</i> , 2020, 24, 65-70.	0.9	7
175	Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients. <i>British Journal of Radiology</i> , 2020, 93, 20200645.	1.0	13
176	Stereotactic body radiotherapy (SBRT) in metachronous oligometastatic prostate cancer: a systematic review and meta-analysis on the current prospective evidence. <i>British Journal of Radiology</i> , 2020, 93, 20200496.	1.0	15

#	ARTICLE	IF	CITATIONS
177	Bone scan use in the management of metastatic castration-resistant prostate cancer: Survey of practice patterns among Canadian radiation oncologists, medical oncologists, and urologists. Canadian Urological Association Journal, 2020, 14, E601-E603.	0.3	0
178	It's Time.... International Journal of Radiation Oncology Biology Physics, 2020, 108, 572-574.	0.4	2
179	Oligometastasis: Past, Present, Future. International Journal of Radiation Oncology Biology Physics, 2020, 108, 530-538.	0.4	27
180	Long-term palliation of lymph node oligometastatic ovarian carcinoma after repeated stereotactic body radiotherapy: case report. Tumori, 2020, 106, NP63-NP66.	0.6	4
181	Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials. European Urology Oncology, 2020, 3, 582-593.	2.6	32
183	Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 108, 17-26.	0.4	18
184	The myth of pulmonary metastasectomy. British Journal of Cancer, 2020, 123, 499-500.	2.9	17
185	Future of Radiation and Immunotherapy. International Journal of Radiation Oncology Biology Physics, 2020, 108, 3-5.	0.4	21
186	A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients. Scientific Reports, 2020, 10, 13589.	1.6	27
187	Radiation in the Treatment of Oligometastatic and Oligoproggressive Disease. Cancer Journal (Sudbury,) Tj ETQq1 1 0,784314,rgBT /Over 1.0 16		
188	Hepatic Metastasis from Breast Cancer. Seminars in Interventional Radiology, 2020, 37, 518-526.	0.3	6
189	Automated model versus treating physician for predicting survival time of patients with metastatic cancer. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1108-1116.	2.2	23
190	Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendations.. Cancer Treatment and Research Communications, 2020, 25, 100265.	0.7	3
191	Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis. JAMA Network Open, 2020, 3, e2026312.	2.8	51
192	Oligometastatic Disease Management: Finding the Sweet Spot. Frontiers in Oncology, 2020, 10, 617793.	1.3	13
193	Vertebral compression fracture during stereotactic body radiotherapy for spinal metastasis: A rare case of tracking failure. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 866-869.	0.6	1
194	Residual intra-fraction error in robotic spinal stereotactic body radiotherapy without immobilization devices. Physics and Imaging in Radiation Oncology, 2020, 16, 20-25.	1.2	7
195	Challenges in Combining Immunotherapy with Radiotherapy in Recurrent/Metastatic Head and Neck Cancer. Cancers, 2020, 12, 3197.	1.7	16

#	ARTICLE	IF	CITATIONS
196	Image-Guided Radiotherapy â€œ The Unsung Hero of Radiotherapy Development. Clinical Oncology, 2020, 32, 789-791.	0.6	3
197	Radiation Therapy in the Management of Oligometastatic Breast Cancer: Current Evidence and Future Directions. Current Breast Cancer Reports, 2020, 12, 266-274.	0.5	0
198	Physician-Predicted Prognosis and Palliative Radiotherapy Treatment Utilization at the End of Life: An Audit of a Large Cancer Center Network. Journal of Pain and Symptom Management, 2020, 60, 898-905.e7.	0.6	2
199	Oligometastatic Disease and Local Therapies. Cancer Journal (Sudbury, Mass ), 2020, 26, 144-148.	1.0	8
200	Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2020, 21, 534-544.	1.1	10
201	Oligometastatic and Oligoprogression Disease and Local Therapies in Prostate Cancer. Cancer Journal (Sudbury, Mass ), 2020, 26, 137-143.	1.0	20
202	Local Ablative Therapies for Oligometastatic and Oligoprogressive Nonâ€œSmall Cell Lung Cancer. Cancer Journal (Sudbury, Mass ), 2020, 26, 129-136.	1.0	7
203	Role of radiation oncology in modern multidisciplinary cancer treatment. Molecular Oncology, 2020, 14, 1431-1441.	2.1	18
204	The Utility of Liquid Biopsies in Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2020, 107, 873-886.	0.4	14
205	[ <sup>18</sup> F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. BMJ Open, 2020, 10, e035959.	0.8	8
206	Oligometastasis and local ablation in the era of systemic targeted and immunotherapy. Radiation Oncology, 2020, 15, 92.	1.2	31
207	Local treatment for liver oligometastases in breast cancer patients: identification of prognostic factors and exploration of appropriate treatment strategy. Translational Cancer Research, 2020, 9, 1225-1234.	0.4	1
208	Salvage radiotherapy in patients affected by oligorecurrent pelvic nodal prostate cancer. Clinical and Translational Oncology, 2020, 22, 2236-2243.	1.2	4
209	Phase 2 Study of Stereotactic Body Radiation Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2020, 108, 707-715.	0.4	29
210	&lt;p&gt;Metastatic Hormone-sensitive Prostate Cancer:â€œCurrent Perspective on the Evolving Therapeutic Landscape&lt;/p&gt;. OncoTargets and Therapy, 2020, Volume 13, 3571-3581.	1.0	23
211	Stereotactic body radiotherapy (SBRT) in patients with lung metastases - prognostic factors and long-term survival using patient self-reported outcome (PRO). BMC Cancer, 2020, 20, 442.	1.1	5
212	Beyond Oligometastases. International Journal of Radiation Oncology Biology Physics, 2020, 107, 253-256.	0.4	15
213	Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?. Lung Cancer, 2020, 144, 76-84.	0.9	29

#	ARTICLE	IF	CITATIONS
214	Pulmonary Metastasectomy in Colorectal Cancer: updated analysis of 93 randomized patients â€“ control survival is much better than previously assumed. <i>Colorectal Disease</i> , 2020, 22, 1314-1324.	0.7	135
215	Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases. <i>BMC Cancer</i> , 2020, 20, 402.	1.1	13
216	Roadmap for metal nanoparticles in radiation therapy: current status, translational challenges, and future directions. <i>Physics in Medicine and Biology</i> , 2020, 65, 21RM02.	1.6	101
217	Stereotactic ablative radiotherapy for the comprehensive treatment of 1â€“3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial. <i>BMC Cancer</i> , 2020, 20, 380.	1.1	75
218	Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2830-2838.	0.8	683
219	Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 813-820.	1.0	22
220	Stereotactic body radiation therapy in the treatment of ovarian cancer. <i>Radiation Oncology</i> , 2020, 15, 108.	1.2	18
221	Combining Radiation with Immunotherapy: The University of Pennsylvania Experience. <i>Seminars in Radiation Oncology</i> , 2020, 30, 173-180.	1.0	6
222	Intraoperative radiotherapy with low energy x-rays for primary and recurrent soft-tissue sarcomas. <i>Radiation Oncology</i> , 2020, 15, 110.	1.2	7
223	Complete and Durable Response After Radiation Therapy to Primary Tumor Site of a Patient With Metastatic Anorectal Mucosal Melanoma With Oligoprogression on Nivolumab. <i>Advances in Radiation Oncology</i> , 2020, 5, 503-510.	0.6	4
224	Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 495-502.	1.1	23
225	Liver Stereotactic Ablative Radiotherapy: an Effective and Feasible Alternative to Surgery during the COVID-19 Pandemic. <i>Clinical Oncology</i> , 2020, 32, 477.	0.6	4
226	Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. <i>European Journal of Cancer</i> , 2020, 134, 41-51.	1.3	46
227	Stereotactic Radiation Therapy Combined With Immunotherapy Against Metastatic Melanoma: Long-Term Results of a Phase 1 Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 150-156.	0.4	11
228	Treatment of the primary in metastatic prostate cancer. <i>Current Opinion in Urology</i> , 2020, 30, 566-575.	0.9	4
229	A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration. <i>Clinical Cancer Research</i> , 2020, 26, 4551-4558.	3.2	49
230	Clinical features and prognostic factors for extracranial oligometastatic breast cancer in China. <i>International Journal of Cancer</i> , 2020, 147, 3199-3205.	2.3	8
231	Radiotherapy treatment volumes for oligorecurrent nodal prostate cancer: a systematic review. <i>Acta Oncologica</i> , 2020, 59, 1224-1234.	0.8	27

#	ARTICLE	IF	CITATIONS
232	Image guidance in radiation therapy for better cure of cancer. <i>Molecular Oncology</i> , 2020, 14, 1470-1491.	2.1	63
233	Perfluorocarbon nanodroplets stabilized with cisplatin-prodrug-constructed lipids enable efficient tumor oxygenation and chemo-radiotherapy of cancer. <i>Nanoscale</i> , 2020, 12, 14764-14774.	2.8	25
234	A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 189-195.	0.4	15
235	Primary CNS Metastatic BRAF-mutated Lung Adenocarcinoma With Complete Intracranial Response to BRAF/MEK Inhibition. <i>Clinical Lung Cancer</i> , 2020, 21, e544-e546.	1.1	3
236	Flattening the Curve of Prostate Cancer Progression: Accurate Detection and Safe Ablation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 609-612.	0.4	0
237	Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 917-926.	0.4	11
238	Recent prospective data regarding good survival outcome after radiofrequency ablation of lung metastases from colorectal cancer: the radiation oncologist point of view. <i>Quantitative Imaging in Medicine and Surgery</i> , 2020, 10, 1182-1185.	1.1	1
239	A phase II randomized trial of Radium-223 dichloride and SABR Versus SABR for oligometastatic prostate cancer (RAVENS). <i>BMC Cancer</i> , 2020, 20, 492.	1.1	16
240	Overall and chemotherapy-free survival following stereotactic body radiation therapy for abdominopelvic oligometastases. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 563-569.	0.9	2
241	Spine stereotactic radiosurgery for metastases from hepatobiliary malignancies: patient selection using PRISM scoring. <i>Journal of Neuro-Oncology</i> , 2020, 148, 327-334.	1.4	3
242	Management of Oligometastatic Disease in Advanced Non-Small Cell Lung Cancer. <i>Clinics in Chest Medicine</i> , 2020, 41, 249-258.	0.8	6
243	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. <i>BMC Cancer</i> , 2020, 20, 557.	1.1	29
244	Immunotherapy and Radiation Therapy for Non-Small Cell Lung Cancer—A Stimulating Partnership. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 360-368.	0.8	2
245	Increased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate Cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 982-985.	0.4	12
246	Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2289-2297.	1.2	12
247	Radiotherapy treatment for lung cancer: Current status and future directions. <i>Respirology</i> , 2020, 25, 61-71.	1.3	142
248	Translating the Immunobiology of SBRT to Novel Therapeutic Combinations for Advanced Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 830.	1.3	6
249	Stereotactic Ablative Radiotherapy for Recurrent or Metastatic Gynecological Cancer: Extending Lives?. <i>Current Treatment Options in Oncology</i> , 2020, 21, 58.	1.3	11

#	ARTICLE	IF	CITATIONS
250	Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 565-573.	1.7	9
251	Curative Intent Radiotherapy Delivered Within the Last Year of Life. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 168-172.	0.6	0
252	Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. <i>Nature Reviews Urology</i> , 2020, 17, 271-291.	1.9	32
253	Update on Systemic Therapy for Advanced Soft Tissue Sarcoma. <i>Current Oncology</i> , 2020, 26, .	0.9	2
254	Stereotactic ablative radiotherapy for oligometastatic breast cancer in elderly patients. <i>Translational Cancer Research</i> , 2020, 9, S197-S206.	0.4	0
255	Vertebral Fractures Following Stereotactic Body Radiotherapy for Spine Oligometastases: A Multi-institutional Analysis of Patient Outcomes. <i>Clinical Oncology</i> , 2020, 32, 433-441.	0.6	10
256	Local treatment of "Oligometastases": Wishful thinking is not supported by available evidence. <i>Clinical Oncology</i> , 2020, 32, 409.	0.6	1
257	Clinical Outcomes of Stereotactic MR-Guided Adaptive Radiation Therapy for High-Risk Lung Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 270-278.	0.4	71
258	The Utility of Stereotactic Ablative Radiation Therapy for Palliation of Metastatic Pancreatic Adenocarcinoma. <i>Practical Radiation Oncology</i> , 2020, 10, 274-281.	1.1	8
259	Clinical utilization of radiation therapy in Korea, 2016. <i>Journal of Radiation Research</i> , 2020, 61, 249-256.	0.8	8
260	Patient-Reported Outcomes of Oligometastatic Patients After Conventional or Stereotactic Radiation Therapy to Bone Metastases: An Analysis of the PRESENT Cohort. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 39-47.	0.4	16
261	Radiation therapy for oligometastatic oropharyngeal cancer. <i>BJR   case Reports</i> , 2020, 6, 20190021.	0.1	2
262	Challenges in the treatment of breast cancer brain metastases: evidence, unresolved questions, and a practical algorithm. <i>Clinical and Translational Oncology</i> , 2020, 22, 1698-1709.	1.2	9
263	Oligometastatic head and neck cancer: Comprehensive review. <i>Head and Neck</i> , 2020, 42, 2194-2201.	0.9	30
264	Outcomes of stereotactic body radiotherapy 60%Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors. <i>Radiation Oncology</i> , 2020, 15, 61.	1.2	23
265	Bench to Bedside: Animal Models of Radiation Induced Musculoskeletal Toxicity. <i>Cancers</i> , 2020, 12, 427.	1.7	5
266	Technology-driven research for radiotherapy innovation. <i>Molecular Oncology</i> , 2020, 14, 1500-1513.	2.1	60
267	Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. <i>Head and Neck</i> , 2020, 42, 1939-1953.	0.9	29

#	ARTICLE	IF	CITATIONS
268	Evaluating single-institution resource costs of consolidative radiotherapy for oligometastatic non-small cell lung cancer using time-driven activity-based costing. <i>Clinical and Translational Radiation Oncology</i> , 2020, 23, 80-84.	0.9	4
269	Curing Metastatic Disease with Radiation Therapy: Myth or Reality? Arguing for Reality. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 429-432.	0.4	3
270	30-day mortality following palliative radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 570-579.	0.9	10
271	Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 987.	1.3	19
272	The Evolving Role of Radiation Therapy in Patients with Metastatic Soft Tissue Sarcoma. <i>Current Oncology Reports</i> , 2020, 22, 79.	1.8	13
273	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1119-1134.	0.6	485
274	Mature Imaging-Based Outcomes Supporting Local Control for Complex Reirradiation Salvage Spine Stereotactic Body Radiotherapy. <i>Neurosurgery</i> , 2020, 87, 816-822.	0.6	10
275	Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002). <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 1034-1043.	1.0	29
276	Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis. <i>Cancer Journal (Sudbury, Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	0.0	15
277	Stereotactic ablative radiotherapy for malignant mediastinal and hilar lymphadenopathy: a systematic review. <i>Journal of Thoracic Disease</i> , 2020, 12, 2280-2287.	0.6	6
278	The Capital Investment Strategy for Radiation therapy in Ontario: A Framework to Ensure Access to Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2020, 5, 318-324.	0.6	5
279	Multi-institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicity. <i>Journal of Surgical Oncology</i> , 2020, 122, 877-883.	0.8	24
280	Long-term clinical outcomes of salvage pelvic radiation therapy for oligo-recurrent pelvic lymph nodes after definitive external-beam radiation therapy for non-metastatic prostate cancer. <i>Journal of Radiation Research</i> , 2020, 61, 622-628.	0.8	5
281	Single-fraction stereotactic ablative body radiotherapy for sternal metastases in oligometastatic breast cancer: Technique and single institution experience. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 580-585.	0.9	4
282	NICE Guidelines: management of colorectal cancer metastases. <i>British Journal of Surgery</i> , 2020, 107, e357-e357.	0.1	9
283	Restricted bowel loop contouring: Improving efficiency in radiotherapy contouring for abdomino-pelvic Stereotactic Ablative Radiotherapy (SABR). <i>Clinical and Translational Radiation Oncology</i> , 2020, 24, 60-64.	0.9	0
284	Thoracic Radiation Oncology Clinical Trial Accrual and Reasons for Nonenrollment: Results of a Large, Prospective, Multiyear Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 897-908.	0.4	2
285	Delivery of magnetic resonance-guided single-fraction stereotactic lung radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 14, 17-23.	1.2	61



#	ARTICLE	IF	CITATIONS
287	Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?. <i>Radiotherapy and Oncology</i> , 2020, 150, 184-190.	0.3	12
288	Cancer oligometastases heterogeneity: Standardizing nomenclature. In regard to defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. <i>Radiotherapy and Oncology</i> , 2020, 149, 247-248.	0.3	0
289	A Novel Salvage Option for Local Failure in Prostate Cancer, Reirradiation Using External Beam or Stereotactic Radiation Therapy: Systematic Review and Meta-Analysis. <i>Advances in Radiation Oncology</i> , 2020, 5, 965-977.	0.6	29
290	Stereotactic Body Radiation Therapy for Nonspine Bone Metastases: International Practice Patterns to Guide Treatment Planning. <i>Practical Radiation Oncology</i> , 2020, 10, e452-e460.	1.1	24
291	Novel radiation therapy approaches for breast cancer treatment. <i>Seminars in Oncology</i> , 2020, 47, 209-216.	0.8	29
292	Local Ablative Therapies in Oligometastatic NSCLC: New Data and New Directions. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 369-376.	0.8	3
293	Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients. <i>Radiation Oncology</i> , 2020, 15, 30.	1.2	36
294	Oligoreview of Non-Small Cell Lung Cancer Oligometastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 455-459.	0.4	3
295	Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 304-313.	0.4	42
296	Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 62-71.	0.4	25
297	Stereotactic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. <i>Lung Cancer</i> , 2020, 142, 70-79.	0.9	17
298	The abscopal effect 67 years later: from a side story to center stage. <i>British Journal of Radiology</i> , 2020, 93, 20200042.	1.0	73
301	The Role of <sup>68</sup> Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1331-1336.	2.8	106
302	ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI. <i>Lung Cancer</i> , 2020, 142, 41-46.	0.9	44
303	Molecular Mechanisms of Radiation-Induced Cancer Cell Death: A Primer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 41.	1.8	203
304	Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure. <i>Thoracic Cancer</i> , 2020, 11, 1038-1044.	0.8	0
305	Five-year survival of patients in control groups of randomized controlled trials is much higher than that assumed in observational study reports. <i>International Journal of Colorectal Disease</i> , 2020, 35, 941-942.	1.0	1
306	The financial impact of SBRT for oligometastatic disease: A population-level analysis in Belgium. <i>Radiotherapy and Oncology</i> , 2020, 145, 215-222.	0.3	8

#	ARTICLE	IF	CITATIONS
307	Treatment of Primary in Metastatic Prostate Cancer. Cancer Journal (Sudbury, Mass ), 2020, 26, 83-86.	1.0	1
308	Clinically Lymph Node Positive Prostate Cancer: At the Intersection of Focal and Systemic Disease Control. Cancer Journal (Sudbury, Mass ), 2020, 26, 53-57.	1.0	1
309	Radiotherapy in the Management of Metastatic Hormone-Sensitive Prostate Cancer. Cancer Journal (Sudbury, Mass ), 2020, 26, 87-93.	1.0	4
310	Effectivity and applicability of the German DEGRO/DGK-guideline for radiotherapy in CIED-bearing patients. Radiotherapy and Oncology, 2020, 152, 208-215.	0.3	15
311	Stereotactic ablative radiation therapy for pulmonary metastases: Improving overall survival and identifying subgroups at high risk of local failure. Radiotherapy and Oncology, 2020, 145, 178-185.	0.3	20
312	Radiotherapy and Immunotherapy for Cancer: From "Systemic" to "Multisite". Clinical Cancer Research, 2020, 26, 2777-2782.	3.2	103
313	Points to consider regarding the SABR-COMET trial " Authors' reply. Lancet, The, 2020, 395, e20.	6.3	4
314	Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline Summary. JCO Oncology Practice, 2020, 16, 83-86.	1.4	13
315	Correlation of dosimetric factors with the development of symptomatic radiation pneumonitis in stereotactic body radiotherapy. Radiation Oncology, 2020, 15, 33.	1.2	19
316	Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1227-1234.	1.2	5
317	Surveillance Outcomes and Intensity of Salvage Therapy Among Human Papillomavirus"Associated Oropharyngeal Cancers. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 311.	1.2	0
318	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	0.9	278
319	Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy. Radiation Oncology, 2020, 15, 24.	1.2	8
320	Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy" a multicenter retrospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1852-1863.	3.3	16
321	A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer. Cancers, 2020, 12, 132.	1.7	7
322	The Emerging Role of Local Therapy in Metastatic Prostate Cancer. Current Oncology Reports, 2020, 22, 2.	1.8	7
323	Expanding the role of small-molecule PSMA ligands beyond PET staging of"prostate cancer. Nature Reviews Urology, 2020, 17, 107-118.	1.9	41
324	Oligometastatic Breast Cancer: Is This a Curable Entity? A Contemporary Review of the Literature. Current Oncology Reports, 2020, 22, 15.	1.8	23

#	ARTICLE	IF	CITATIONS
325	Surgical treatment of pulmonary metastases in the Netherlands: data from the Dutch Lung Cancer Audit for Surgery. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 58, 768-774.	0.6	20
326	Clinical outcomes, local/regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab. <i>Radiotherapy and Oncology</i> , 2020, 149, 205-211.	0.3	39
327	Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2351-2358.	1.2	21
328	Significant reduction of oncologic pulmonary death by local control for pulmonary oligometastases treated with stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 147, 86-91.	0.3	2
329	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 650.	3.4	696
330	Systemic Therapy Plus Thermal Ablation Versus Systemic Therapy Alone for Oligometastatic Liver Metastases from Non-small Cell Lung Cancer. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1285-1293.	0.9	6
331	An integrated quality assurance phantom for frameless single-isocenter multitarget stereotactic radiosurgery. <i>Physics in Medicine and Biology</i> , 2020, 65, 115006.	1.6	15
332	Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies: a multi-institutional analysis. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 865-872.	1.2	15
333	Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. <i>Radiotherapy and Oncology</i> , 2020, 148, 157-166.	0.3	352
334	Imaging response assessment following stereotactic body radiotherapy for solid tumour metastases of the spine: Current challenges and future directions. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 385-397.	0.9	6
335	Radiomics for liver tumours. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 888-899.	1.0	20
336	The European Organisation for Research and Treatment of Cancer, State of Science in radiation oncology and priorities for clinical trials meeting report. <i>European Journal of Cancer</i> , 2020, 131, 76-88.	1.3	15
337	Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Esophageal Cancer: Results and Prognostic Factors. <i>Anticancer Research</i> , 2020, 40, 2065-2072.	0.5	11
338	Clinical Outcomes and Prognostic Factors of Patients With Esophageal Squamous Cell Carcinoma With Oligo-recurrence Treated With Radical Re-irradiation. <i>Anticancer Research</i> , 2020, 40, 2387-2392.	0.5	2
339	Stereotactic Radiotherapy for Ultra-Central Lung Oligometastases in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 885.	1.7	10
340	Oligometastases: history of a hypothesis. <i>Annals of Palliative Medicine</i> , 2021, 10, 5923-5930.	0.5	26
341	Commentary: Think systemically, act locally. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 1505-1506.	0.4	0
342	A drug delivery perspective on intratumoral-immunotherapy in renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 338-345.	0.8	2

#	ARTICLE	IF	CITATIONS
343	Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 143-151.	3.3	25
344	Pulmonary resection is associated with long-term survival and should remain a therapeutic option in oligometastatic lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 1497-1504.e2.	0.4	30
345	Primary Parotid Merkel Type Small Cell Neuroendocrine Carcinoma with Oligometastasis to the Brain and Adrenal Gland: Case Report and Review of Literature. <i>Head and Neck Pathology</i> , 2021, 15, 311-318.	1.3	5
346	Commentary: Surgery expanding to stage IV non-“small cell lung cancer treatment?!. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 1508-1509.	0.4	1
347	Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 447-455.	2.6	52
348	Stereotactic ablative radiotherapy for colorectal cancer liver metastasis. <i>Seminars in Cancer Biology</i> , 2021, 71, 21-32.	4.3	14
349	Stereotactic Pelvic Reirradiation for Locoregional Cancer Relapse. <i>Clinical Oncology</i> , 2021, 33, e15-e21.	0.6	2
350	Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for 18F-fluciclovine-PET/CT in delineating sites of recurrence and identifying patients with oligometastatic disease. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 365.e9-365.e16.	0.8	12
351	Safety of palbociclib concurrent with palliative pelvic radiotherapy: discussion of a case of increased toxicity and brief review of literature. <i>Journal of Medical Radiation Sciences</i> , 2021, 68, 96-102.	0.8	10
352	A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions. <i>Annals of Palliative Medicine</i> , 2020, 9, 34-34.	0.5	12
353	Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 387-395.	0.4	19
354	Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 391-404.	2.0	25
355	Conformal Avoidance of Normal Organs at Risk by Perfusion-Modulated Dose Sculpting in Tumor Single-Dose Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 288-297.	0.4	7
356	Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies. <i>Clinical Oncology</i> , 2021, 33, 50-56.	0.6	14
357	Cost-Effectiveness Analysis of Stereotactic Ablative Radiation Therapy in Patients With Oligometastatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1185-1194.	0.4	18
358	PulMiCC and data from other randomized controlled trials challenge the usefulness of metastasectomy. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 59, 513-514.	0.6	4
359	Practical Considerations for the Implementation of a Stereotactic Body Radiation Therapy Program for Oligo-Metastases. <i>Advances in Radiation Oncology</i> , 2021, 6, 100499.	0.6	0
360	Dose coverage impacts local control in ultra-central lung oligometastases treated with stereotactic radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 396-404.	1.0	8

#	ARTICLE	IF	CITATIONS
361	Technical challenges of linac-based stereotactic ablative body radiotherapy: short review for non-radiation oncologists. <i>Annals of Palliative Medicine</i> , 2021, 10, 5931-5943.	0.5	1
362	Metastatic Disease as a Distinct Discipline in Radiation Oncology. <i>JAMA Oncology</i> , 2021, 7, 21.	3.4	8
363	Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined With Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 396-412.	0.4	37
364	Safety, Efficacy, and Patterns of Failure After Single-Fraction Stereotactic Body Radiation Therapy (SBRT) for Oligometastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 756-763.	0.4	17
365	A multi-institutional phase 2 trial of stereotactic body radiotherapy in the treatment of bone metastases in pediatric and young adult patients with sarcoma. <i>Cancer</i> , 2021, 127, 739-747.	2.0	16
366	Trends in Radiation Therapy for Bone Metastases, 2015 to 2017: Choosing Wisely in the Era of Complex Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 923-931.	0.4	10
367	Metastasis-directed therapy for oligometastasis and beyond. <i>British Journal of Cancer</i> , 2021, 124, 136-141.	2.9	16
368	External Beam Radiation Therapy for Liver Metastases. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 159-173.	0.6	14
369	Marker-less online MR-guided stereotactic body radiotherapy of liver metastases at a 1.5T MR-Linac – Feasibility, workflow data and patient acceptance. <i>Clinical and Translational Radiation Oncology</i> , 2021, 26, 55-61.	0.9	30
370	Palliative Radiation Therapy for Metastatic, Persistent, or Recurrent Epithelial Ovarian Cancer: Efficacy in the Era of Modern Technology and Targeted Agents. <i>Advances in Radiation Oncology</i> , 2021, 6, 100624.	0.6	5
371	Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma. <i>BJU International</i> , 2021, 127, 703-711.	1.3	20
372	Stereotactic Ablative Radiation Therapy to All Lesions in Patients With Oligometastatic Cancers: A Phase 1 Dose-Escalation Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1195-1205.	0.4	12
374	Development of staffing, workload and infrastructure in member departments of the European Organisation for Research and Treatment of Cancer (EORTC) radiation oncology group. <i>Radiotherapy and Oncology</i> , 2021, 155, 226-231.	0.3	12
375	Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer. <i>JAMA Oncology</i> , 2021, 7, 92.	3.4	114
376	Biology-guided radiotherapy: redefining the role of radiotherapy in metastatic cancer. <i>British Journal of Radiology</i> , 2021, 94, 20200873.	1.0	44
377	Treatment Options in Oligometastatic Disease in Prostate Cancer: Thinking Outside the Box. <i>Current Treatment Options in Oncology</i> , 2021, 22, 2.	1.3	1
378	Defining the needs of patients with recurrent and/or metastatic head and neck cancer: An expert opinion. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103200.	2.0	9
379	Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1176-1184.	0.4	27

#	ARTICLE	IF	CITATIONS
380	Reply to: The course of lung oligometastatic colorectal cancer may be a reflection of selection for treatment rather than an effect of stereotactic body radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 76-78.	1.0	2
381	Recursive Partitioning Analysis for Local Control Achieved With Stereotactic Body Radiation Therapy for the Liver, Spine, or Lymph Nodes. <i>Advances in Radiation Oncology</i> , 2021, 6, 100612.	0.6	5
382	The course of lung oligometastatic colorectal cancer may be a reflection of selection for treatment rather than an effect of stereotactic body radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 74-75.	1.0	1
384	Pulmonary Metastasectomy for Colorectal Cancer: Randomized Controlled Trial. <i>Radiology</i> , 2021, 298, E54-E55.	3.6	1
385	Identifying an oligometastatic phenotype in HPV-associated oropharyngeal squamous cell cancer: Implications for clinical trial design. <i>Oral Oncology</i> , 2021, 112, 105046.	0.8	11
386	Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network. <i>Radiotherapy and Oncology</i> , 2021, 155, 151-159.	0.3	13
387	Advanced Radiation Therapy Technology Use in the Treatment of Bone Metastases in a Public, Salary-Funded, Non-Incentivized Health Care System. <i>JCO Oncology Practice</i> , 2021, 17, e178-e185.	1.4	6
388	Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 30-37.	0.8	239
389	Oligometastatic breast cancer: where are we now and where are we headed? a narrative review. <i>Annals of Palliative Medicine</i> , 2020, 9, 62-62.	0.5	29
390	Onco-ontogeny recapitulates phylogeny a consideration. <i>Oncogene</i> , 2021, 40, 1542-1550.	2.6	1
391	CT-Guided Interstitial HDR Brachytherapy for Malignant Lung Lesions: Experience from University of California Los Angeles. , 2021, , 153-178.		0
394	Provisional Clinical Opinions for Radiation Therapy in Pre frail Elderly Colorectal Cancer Patients: Part Two. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2021, 74, 422-429.	0.1	0
395	Radiation-induced abscopal reproductive effect is driven by TNF- $\alpha$ /p38 MAPK/Rac1 axis in Sertoli cells. <i>Theranostics</i> , 2021, 11, 5742-5758.	4.6	10
396	Liquid Biopsy Cell-free DNA Biomarkers in Patients With Oligometastatic Colorectal Cancer Treated by Ablative Radiotherapy. <i>Anticancer Research</i> , 2021, 41, 829-834.	0.5	9
397	(Oligo)metastasis as a Spectrum of Disease. <i>Cancer Research</i> , 2021, 81, 2577-2583.	0.4	22
398	A systematic review and practical considerations of stereotactic body radiotherapy in the treatment of head and neck cancer. <i>British Journal of Radiology</i> , 2021, 94, 20200332.	1.0	12
399	Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the TOAST™ database. <i>Radiation Oncology</i> , 2021, 16, 4.	1.2	20
400	Radiation Therapy for Chondrosarcoma. , 2021, , 203-253.		0

#	ARTICLE	IF	CITATIONS
401	The Role of Radiation Therapy in the Older Patient. <i>Current Oncology Reports</i> , 2021, 23, 11.	1.8	7
402	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>Radiotherapy and Oncology</i> , 2021, 154, 327-353.	0.3	96
403	Therapeutic enhancement of radiation and immunomodulation by gold nanoparticles in triple negative breast cancer. <i>Cancer Biology and Therapy</i> , 2021, 22, 124-135.	1.5	28
404	National variation in pulmonary metastasectomy for colorectal cancer. <i>Colorectal Disease</i> , 2021, 23, 1306-1316.	0.7	10
405	Whole-body magnetic resonance imaging: technique, guidelines and key applications. <i>Ecancermedicalscience</i> , 2021, 15, 1164.	0.6	18
406	Benefits of local consolidative treatment in oligometastases of solid cancers: a stepwise-hierarchical pooled analysis and systematic review. <i>Npj Precision Oncology</i> , 2021, 5, 2.	2.3	10
407	Radiotherapy for Oligometastatic Prostate Cancer. <i>Practical Guides in Radiation Oncology</i> , 2021, , 209-222.	0.0	0
408	Metaplastic Breast Carcinoma: Experience of a Tertiary Cancer Center in the Middle East. <i>Cancer Control</i> , 2021, 28, 107327482110048.	0.7	14
409	Evaluating dose constraints for radiation induced liver damage following magnetic resonance image guided Stereotactic Body radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 17, 91-94.	1.2	7
410	Stereotactic Body Radiation Therapy (SBRT) for a Patient with a Myocardial Metastasis: A Case Report. <i>Current Oncology</i> , 2021, 28, 390-395.	0.9	0
411	Phase II Trial Investigating Definitive Radiation Therapy in Lieu of Systemic Therapy for Oligometastatic Renal Cell Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
412	Potential Advanced Drug Delivery Systems Based on Hydrogels in 3D Printing Technology for Cancer Treatment. <i>Materials Forming, Machining and Tribology</i> , 2021, , 323-348.	0.7	0
413	High-dose-rate surface brachytherapy as a treatment option for renal cell carcinoma cutaneous metastases. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 331-337.	0.4	1
414	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. <i>European Urology</i> , 2021, 80, 632-640.	0.9	61
415	Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer. <i>Cancers</i> , 2021, 13, 248.	1.7	4
416	Advances in Breast Cancer Radiation Therapy. <i>Current Breast Cancer Reports</i> , 2021, 13, 49-55.	0.5	1
417	Postoperative Stereotactic Body Radiotherapy for Spinal Metastasis and Predictors of Local Control. <i>Neurosurgery</i> , 2021, 88, 1021-1027.	0.6	12
418	Development and Implementation of an Online Adaptive Stereotactic Body Radiation Therapy Workflow for Treatment of Intracardiac Metastasis. <i>Practical Radiation Oncology</i> , 2021, 11, e395-e401.	1.1	3

#	ARTICLE	IF	CITATIONS
419	Commentary: A crusade against current pulmonary metastasectomy practice in colorectal cancer patients: Do the con arguments remain after the PulMiCC trial?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 491-492.	0.4	1
420	Impact of reirradiation, chemotherapy, and immunotherapy on survival of patients with recurrent lung cancer: A single-center retrospective analysis. <i>Thoracic Cancer</i> , 2021, 12, 1162-1170.	0.8	5
421	Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician's guide. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 641-655.	1.1	8
422	MR-Guided Radiotherapy: The Perfect Partner for Immunotherapy?. <i>Frontiers in Oncology</i> , 2020, 10, 615697.	1.3	6
423	X-change symposium: status and future of modern radiation oncology—from technology to biology. <i>Radiation Oncology</i> , 2021, 16, 27.	1.2	1
424	A unified multi-activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS). <i>Medical Physics</i> , 2021, 48, 2038-2049.	1.6	3
425	Stereotactic Ablative Radiotherapy for the Management of Liver Metastases from Neuroendocrine Neoplasms: A Preliminary Study. <i>Neuroendocrinology</i> , 2022, 112, 153-160.	1.2	10
427	Dysbiotic stress increases the sensitivity of the tumor vasculature to radiotherapy and c-Met inhibitors. <i>Angiogenesis</i> , 2021, 24, 597-611.	3.7	3
428	Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer. <i>BMJ Open</i> , 2021, 11, e041345.	0.8	3
429	Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges. <i>Frontiers in Oncology</i> , 2020, 10, 608772.	1.3	30
430	Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab010.	1.4	21
431	Stereotactic body radiotherapy for synchronous early stage non-small cell lung cancer. <i>Acta Oncologica</i> , 2021, 60, 605-612.	0.8	6
432	Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study. <i>Lung Cancer</i> , 2021, 152, 119-126.	0.9	17
433	ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 153-190.	1.4	99
434	Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1-5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e043628.	0.8	6
435	Interstitial single fraction brachytherapy for malignant pulmonary tumours. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 416-422.	1.0	3
436	Clinical application of circulating tumor DNA in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1431-1442.	1.2	5
437	Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR). <i>BMC Cancer</i> , 2021, 21, 303.	1.1	13



#	ARTICLE	IF	CITATIONS
438	The influence of 68Ga-prostate-specific membrane antigen PET/computed tomography on prostate cancer staging and planning of definitive radiation therapy. <i>Nuclear Medicine Communications</i> , 2021, 42, 811-817.	0.5	3
439	Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis. <i>International Journal of Cancer</i> , 2021, 149, 358-370.	2.3	24
440	PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3975-3989.	3.3	25
442	Feasibility and Clinical Value of CT-Guided 125I Brachytherapy for Pain Palliation in Patients With Breast Cancer and Bone Metastases After External Beam Radiotherapy Failure. <i>Frontiers in Oncology</i> , 2021, 11, 627158.	1.3	3
443	Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated With Stereotactic Body Radiotherapy Using 68Ga-PSMA PET/CT. <i>Clinical Nuclear Medicine</i> , 2021, 46, 465-470.	0.7	17
444	High-risk, recurrent and oligometastatic prostate cancer: recent developments on the role of radiation. <i>Current Opinion in Oncology</i> , 2021, 33, 238-243.	1.1	2
445	Stereotactic radiotherapy to oligoprogressive lesions detected with 68Ga-PSMA-PET/CT in castration-resistant prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3683-3692.	3.3	21
446	Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 596-604.	2.8	79
447	Adoption of single fraction radiotherapy for uncomplicated bone metastases in a tertiary centre. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 64-69.	0.9	6
448	Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. <i>European Urology Oncology</i> , 2021, 4, 714-730.	2.6	16
449	The roles of surgery, stereotactic radiation, and ablation for treatment of pulmonary metastases. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 495-502.	0.4	22
450	Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S. <i>Oncologist</i> , 2021, 26, e905-e906.	1.9	8
451	Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103242.	2.0	7
452	Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021, 26, 325-340.	0.3	3
453	Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response. <i>Frontiers in Oncology</i> , 2020, 10, 627379.	1.3	24
454	Oligometastatic head and neck cancer: Which patients benefit from radical local treatment of all tumour sites?. <i>Radiation Oncology</i> , 2021, 16, 62.	1.2	13
455	Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 638873.	1.3	23
456	Stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of liver metastases in oligometastatic patients: initial clinical experience. <i>Radiation Oncology Journal</i> , 2021, 39, 33-40.	0.7	29

#	ARTICLE	IF	CITATIONS
458	Late Central Airway Toxicity after High-Dose Radiotherapy: Clinical Outcomes and a Proposed Bronchoscopic Classification. <i>Cancers</i> , 2021, 13, 1313.	1.7	2
460	Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?. <i>Clinical and Translational Oncology</i> , 2021, 23, 1717-1726.	1.2	15
461	Lung metastasectomy for colorectal cancer: The impression of benefit from uncontrolled studies was not supported in a randomized controlled trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 486-490.	0.4	6
462	Radical radiotherapy for paediatric solid tumour metastases: An overview of current European protocols and outcomes of a SIOPE multicenter survey. <i>European Journal of Cancer</i> , 2021, 145, 121-131.	1.3	5
464	Pulmonary metastasectomy: limits to credibility. <i>Journal of Thoracic Disease</i> , 2021, 13, 2603-2610.	0.6	2
465	Vertebral compression fracture rate following stereotactic ablative body radiotherapy for spine oligometastases: a UK experience. <i>Journal of Radiotherapy in Practice</i> , 2022, 21, 476-480.	0.2	1
467	Classification and Treatment of Oligometastatic Disease in Non-Small-Cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2021, 61, 95-99.	0.0	0
468	Radioembolization Outside of the Liver. <i>Digestive Disease Interventions</i> , 2021, 05, 137-141.	0.3	1
469	Radiotherapy in the Era of Immunotherapy—With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?. <i>Frontiers in Oncology</i> , 2021, 11, 662236.	1.3	19
470	Magnetic Resonance Imaging-Guided Adaptive Radiotherapy for Colorectal Liver Metastases. <i>Cancers</i> , 2021, 13, 1636.	1.7	12
471	A fatal wound complication following sequential anti-angiogenesis, immune checkpoint inhibition and ultra-hypofractionated radiotherapy. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1121-1125.	0.4	1
472	The importance of an adequate surgical template during salvage lymph node dissection for node-recurrent prostate cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.121.262104.	2.8	0
473	Radiation for Oligometastatic Lung Cancer in the Era of Immunotherapy: What Do We (Need to) Know?. <i>Cancers</i> , 2021, 13, 2132.	1.7	5
474	Emerging Paradigm of Consolidative Thoracic Radiotherapy in Oligometastatic NSCLC. <i>Seminars in Radiation Oncology</i> , 2021, 31, 120-123.	1.0	3
475	Management of Synchronous Extrathoracic Oligometastatic Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 1893.	1.7	10
476	Distinct Outcomes of Oropharyngeal Squamous Cell Carcinoma Patients after Distant Failure According to p16 Status: Implication in Therapeutic Options. <i>Current Oncology</i> , 2021, 28, 1673-1680.	0.9	6
477	Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma. <i>Oral Oncology</i> , 2021, 115, 105213.	0.8	33
478	Stereotactic body radiotherapy for pulmonary oligometastases as an initial metastasis-directed therapy: patterns of relapse and predictive factors for early mortality. <i>Precision Radiation Oncology</i> , 2021, 5, 84-92.	0.4	1

#	ARTICLE	IF	CITATIONS
479	Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1165-1184.	0.8	54
480	Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. <i>Cancer Discovery</i> , 2021, 11, 874-899.	7.7	107
481	Modelling treatment-response rates. <i>Nature Biomedical Engineering</i> , 2021, 5, 295-296.	11.6	0
482	Radiotherapy in nodal oligorecurrent prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 575-580.	1.0	11
483	Radiation and Modulation of the Tumor Immune Microenvironment in Nonâ€“Small Cell Lung Cancer. <i>Seminars in Radiation Oncology</i> , 2021, 31, 133-139.	1.0	6
484	Stereotactic radiotherapy and oligometastases. <i>Lancet Oncology, The</i> , 2021, 22, e132.	5.1	2
485	Synergistic Chemo-thermal Therapy of Cancer by DNA-Templated Silver Nanoclusters and Polydopamine Nanoparticles. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 21653-21660.	4.0	29
486	The Dutchâ€“Belgian Registry of Stereotactic Body Radiation Therapy for Liver Metastases: Clinical Outcomes of 515 Patients and 668 Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1377-1386.	0.4	15
487	Local therapy for oligometastatic esophageal squamous cell carcinoma: a prospective, randomized, Phase II clinical trial. <i>Future Oncology</i> , 2021, 17, 1285-1293.	1.1	5
488	Liver SBRT with active motion-compensation results in excellent local control for liver oligometastases: An outcome analysis of a pooled multi-platform patient cohort. <i>Radiotherapy and Oncology</i> , 2021, 158, 230-236.	0.3	8
489	Stereotactic Ablative Body Radiotherapy for Metastases Needs Better Evidence. <i>JAMA Oncology</i> , 2021, 7, 782.	3.4	0
490	In Silico Single-Fraction Stereotactic Ablative Radiation Therapy for the Treatment of Thoracic and Abdominal Oligometastatic Disease With Online Adaptive Magnetic Resonance Guidance. <i>Advances in Radiation Oncology</i> , 2021, 6, 100652.	0.6	3
491	Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance. <i>Medical Oncology</i> , 2021, 38, 72.	1.2	6
492	Liver Metastasisâ€“Directed Ablative Radiotherapy in Pancreatic Cancer Offers Prolonged Time Off Systemic Therapy in Selected Patients. <i>Pancreas</i> , 2021, 50, 736-743.	0.5	7
493	Novel approach involving stereotactic body radiotherapy followed by intramedullary nail placement for long bone metastases: a case report. <i>Clinical and Experimental Metastasis</i> , 2021, 38, 425-427.	1.7	1
494	Developments in radiation techniques for thoracic malignancies. <i>European Respiratory Review</i> , 2021, 30, 200224.	3.0	6
496	First Asian population study of stereotactic body radiation therapy for ventricular arrhythmias. <i>Scientific Reports</i> , 2021, 11, 10360.	1.6	10
497	Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview. <i>Cancers</i> , 2021, 13, 2394.	1.7	6

#	ARTICLE	IF	CITATIONS
498	The emerging role of local therapy in oligometastatic non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 819-825.	0.4	7
500	A nomogram for predicting brain metastasis in patients with de novo stage IV breast cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 853-853.	0.7	4
501	Outcomes and Prognostic Factors of Patients with Metastatic Colorectal Cancer Who Underwent Pulmonary Metastasectomy with Curative Intent: A Brazilian Experience. <i>Oncologist</i> , 2021, 26, e1581-e1588.	1.9	10
502	Local treatment of metastases plus systemic chemotherapy on overall survival of patients with metastatic nasopharyngeal carcinoma. <i>Head and Neck</i> , 2021, 43, 2423-2433.	0.9	7
503	Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA). <i>Clinical and Translational Radiation Oncology</i> , 2021, 28, 90-96.	0.9	14
505	Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 659987.	1.3	9
506	Benefit of replanning in MR-guided online adaptive radiation therapy in the treatment of liver metastasis. <i>Radiation Oncology</i> , 2021, 16, 84.	1.2	29
507	Radiotherapy for Metastatic Non-small Cell Lung Cancer. <i>Advances in Oncology</i> , 2021, 1, 15-28.	0.1	1
508	Impact of anatomic site of distant metastasis on survival in salivary gland cancers. <i>Head and Neck</i> , 2021, 43, 2589-2601.	0.9	2
509	Role of modern radiotherapy in managing patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2021, 27, 2434-2457.	1.4	18
510	MRI-Guided Radiation Therapy. <i>Advances in Oncology</i> , 2021, 1, 29-39.	0.1	1
512	Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapy. <i>BMC Cancer</i> , 2021, 21, 534.	1.1	11
513	Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care. <i>Current Oncology</i> , 2021, 28, 1857-1866.	0.9	6
514	Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT. <i>Journal of Clinical Medicine</i> , 2021, 10, 2131.	1.0	13
515	PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1747-1750.	2.8	16
516	Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer. <i>Cancer Medicine</i> , 2021, 10, 5163-5174.	1.3	11
517	Challenges in the Treatment of Oligometastatic Non-small Cell Lung Cancer. , 0, , .		0
518	New Therapies and Biomarkers: Are We Ready for Personalized Treatment in Small Cell Lung Cancer?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e276-e285.	1.8	7

#	ARTICLE	IF	CITATIONS
519	Revisiting a Null Hypothesis: Exploring the Parameters of Oligometastasis Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 371-381.	0.4	8
520	Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases. <i>JAMA Oncology</i> , 2021, 7, 845.	3.4	56
521	Outcomes with multi-disciplinary management of central lung tumors with CT-guided percutaneous high dose rate brachyablation. <i>Radiation Oncology</i> , 2021, 16, 99.	1.2	4
522	Surgical Morbidity and Lung Function Changes After Laser-Assisted Pulmonary Metastasectomy: A Prospective Bicentric Study. <i>Frontiers in Surgery</i> , 2021, 8, 646269.	0.6	4
523	Oligometastatic breast cancer: Are we there yet?. <i>International Journal of Cancer</i> , 2021, 149, 1520-1528.	2.3	13
524	Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review. <i>Cancers</i> , 2021, 13, 3278.	1.7	6
525	Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review. <i>European Urology Oncology</i> , 2021, 4, 339-355.	2.6	20
526	Oncological treatment of bone tumours and bone metastases. <i>Orthopaedics and Trauma</i> , 2021, 35, 163-169.	0.2	0
527	Training and Validation of Deep Learning-Based Auto-Segmentation Models for Lung Stereotactic Ablative Radiotherapy Using Retrospective Radiotherapy Planning Contours. <i>Frontiers in Oncology</i> , 2021, 11, 626499.	1.3	13
528	Introductory Chapter: Recent Progress in Lung Cancer Treatment - The Value of Multiple Perspectives. , 0, , .		0
529	Definitive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer: Current Status and Future Perspectives. , 0, , .		0
531	Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD). <i>International Journal of Gynecological Cancer</i> , 2022, 32, 939-943.	1.2	7
532	Stereotactic body radiotherapy for the treatment of gynecologic malignancies: Passing fancy or here to stay?. <i>Gynecologic Oncology</i> , 2021, 161, 642-644.	0.6	0
533	Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer. <i>Radiation Oncology</i> , 2021, 16, 125.	1.2	17
534	Is There a Benefit of Combining Immunotherapy and Radiotherapy in Bladder Cancer?. <i>Clinical Oncology</i> , 2021, 33, 407-414.	0.6	6
535	Radiation Therapy in Non-Small-Cell Lung Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a037713.	2.9	8
536	Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1075-1085.	0.5	19
537	Single-Center Experience of Focal Thermo-Ablative Therapy After Pelvic Radiotherapy for In-Field Prostate Cancer Oligo-Recurrence. <i>Frontiers in Oncology</i> , 2021, 11, 709779.	1.3	1

#	ARTICLE	IF	CITATIONS
538	Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer. PLoS ONE, 2021, 16, e0252041.	1.1	4
539	Mature Experiences Using Local Therapy for Oligometastases. Seminars in Radiation Oncology, 2021, 31, 180-185.	1.0	1
540	Technical Giants But Biologic Infants: Defining a More Sophisticated Role for Local Therapy in Metastatic Disease. Seminars in Radiation Oncology, 2021, 31, 200-204.	1.0	2
541	Local Ablative Therapy in Oligometastatic NSCLC. Seminars in Radiation Oncology, 2021, 31, 235-241.	1.0	1
542	Stereotactic Ablative Radiation (SABR) for Oligometastatic RCC. Seminars in Radiation Oncology, 2021, 31, 227-234.	1.0	9
543	The Spectrum of Metastasis: An Opportunity for Cure?. Seminars in Radiation Oncology, 2021, 31, 174-179.	1.0	7
544	Phase I Trial of Stereotactic Body Radiation Therapy Dose Escalation in Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1003-1012.	0.4	21
545	A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done. Translational Lung Cancer Research, 2021, 10, 3369-3384.	1.3	11
546	Current Evidence for Stereotactic Body Radiotherapy in Lung Metastases. Current Oncology, 2021, 28, 2560-2578.	0.9	7
547	Clinical outcomes of stereotactic magnetic resonance image-guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis. Cancer Medicine, 2021, 10, 5897-5906.	1.3	20
548	Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review. Translational Lung Cancer Research, 2021, 10, 3420-3431.	1.3	5
549	Dosimetric feasibility of hypofractionation for metastatic bone/bone marrow lesions from paediatric solid tumours. Radiotherapy and Oncology, 2021, 160, 166-174.	0.3	1
550	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer, 2021, 151, 72-83.	1.3	12
551	The Economics of Using Locally Ablative Therapy in Oligometastatic Cancer. Seminars in Radiation Oncology, 2021, 31, 250-252.	1.0	1
552	Contemporary radiotherapy: present and future. Lancet, The, 2021, 398, 171-184.	6.3	94
553	Stereotactic Body Radiotherapy for Patients with Lung Oligometastatic Disease: A Five-Year Systematic Review. Cancers, 2021, 13, 3623.	1.7	8
554	Reply: The molecular basis of tumor biology—an evolving field with far-reaching implications in the diagnosis, prognostication, and treatment of our patients. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, e134-e135.	0.4	1
555	Overall survival after recurrence in stage I-III colorectal cancer patients in accordance with the recurrence organ site and pattern. Annals of Gastroenterological Surgery, 2021, 5, 813-822.	1.2	8

#	ARTICLE	IF	CITATIONS
556	Local for advanced, is this a paradox?. <i>Translational Lung Cancer Research</i> , 2021, 10, 3324-3328.	1.3	0
557	Defining oligometastatic hormone sensitive prostate cancer and clinically significant outcomes: Implications on clinical trials?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 431.e1-431.e8.	0.8	2
558	Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective. <i>Frontiers in Oncology</i> , 2021, 11, 722277.	1.3	5
559	Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy â€œ No. <i>Clinical Oncology</i> , 2021, 33, 749-750.	0.6	3
560	Local Therapies in Oligometastatic and Oligoprogressive Prostate Cancer. <i>Seminars in Radiation Oncology</i> , 2021, 31, 242-249.	1.0	7
561	Current and future research efforts in oligometastatic non-small cell lung cancerâ€™a systematic review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3473-3485.	1.3	3
562	Discontinuous stereotactic body radiotherapy schedule increases overall survival in early-stage non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 157, 100-108.	0.9	5
563	Palliative Radiotherapy for Advanced Cancers. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 563-580.	0.6	8
564	Changing pattern of radiation therapy for bone metastases in an Australian population-based cohort of men with prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e7-e15.	0.9	1
565	Phase 3 Multi-Center, Prospective, Randomized Trial Comparing Single-Dose 24 Gy Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 672-679.	0.4	68
566	Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3130-3143.	0.6	9
567	Local ablative therapies in oligometastatic NSCLC-upfront or outback?â€™a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3446-3456.	1.3	7
568	The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3409-3419.	1.3	13
569	Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 737425.	1.3	6
570	Radiation Therapy Planning of Thoracic Tumors: A Review of Challenges Associated With Lung Toxicities and Potential Perspectives of Gallium-68 Lung PET/CT Imaging. <i>Frontiers in Medicine</i> , 2021, 8, 723748.	1.2	12
571	Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 379-389.	0.4	28
572	Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy. <i>Cellular and Molecular Immunology</i> , 2022, 19, 33-45.	4.8	47
573	Local control of 1â€™5 fraction radiotherapy regimens for spinal metastases: an analysis of the impacts of biologically effective dose and primary histology. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021, 26, 883-891.	0.3	2

#	ARTICLE	IF	CITATIONS
574	Oligometastases for Clinicians: Size Matters. <i>Journal of Clinical Oncology</i> , 2021, 39, 2643-2646.	0.8	18
575	An international pooled analysis of SBRT outcomes to oligometastatic spine and non-spine bone metastases. <i>Radiotherapy and Oncology</i> , 2021, 164, 98-103.	0.3	14
576	Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review. <i>Advances in Urology</i> , 2021, 2021, 1-9.	0.6	13
577	Approach to Oligometastatic Cancer in the Elderly Patient. <i>Current Oncology Reports</i> , 2021, 23, 122.	1.8	2
578	Evolving Practice Pattern of Palliative Radiation Therapy for Bone Metastases from Lung Cancer in Australia. <i>Clinical Oncology</i> , 2021, 33, e530-e539.	0.6	2
579	Radiation treatment in prostate cancer: covering the waterfront. <i>BJU International</i> , 2021, 128, 398-407.	1.3	3
580	Online Magnetic Resonance-Guided Radiotherapy (oMRgRT) for Gynecological Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 628131.	1.3	14
582	Authors' Reply: To the Letter to the Editor by Groheux et al. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, xxx-xxxii.	2.3	0
583	Current usage of stereotactic body radiotherapy for oligometastatic prostate cancer in Korea: patterns of care survey (KROG 19-08). <i>Annals of Translational Medicine</i> , 2021, 9, 1291-1291.	0.7	3
584	Thecal Sac Contouring as a Surrogate for the Cauda Equina and Intracanal Spinal Nerve Roots for Spine Stereotactic Body Radiation Therapy (SBRT): Contour Variability and Recommendations for Safe Practice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 114-120.	0.4	11
586	Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 346-353.	0.9	1
587	Treatment Strategies for Oligometastatic Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 94.	1.3	12
588	PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 30, 1-6.	0.9	12
589	Novel imaging strategies for prostate cancer. <i>Future Oncology</i> , 2021, 17, 3545-3548.	1.1	0
590	Radiation Therapy in Metastatic Soft Tissue Sarcoma: From Palliation to Ablation. <i>Cancers</i> , 2021, 13, 4775.	1.7	14
591	Something for Everyone From Low-Risk to High-Risk: 5 Recent Studies to Improve Treatment and Surveillance for All Patients With Squamous Cell Carcinoma of the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1-8.	0.4	0
592	Stereotactic body radiotherapy for osseous low alpha <sup>α</sup> β resistant metastases for pain relief <sup>β</sup> SOLAR-P. <i>Radiation Oncology</i> , 2021, 16, 170.	1.2	0
593	Significance of liver metastasis volume in breast cancer patients treated with stereotactic body radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 247-253.	1.0	1



#	ARTICLE	IF	CITATIONS
594	Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 7009-7031.	0.9	0
595	Addressing hepatic metastases in ovarian cancer: Recent advances in treatment algorithms and the need for a multidisciplinary approach. <i>World Journal of Hepatology</i> , 2021, 13, 1122-1131.	0.8	2
596	American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 361-375.	0.4	22
597	Salvage pulmonary resection in stages IIIb-IV lung cancer after treatment with immune checkpoint inhibitors case series and literature review. <i>Journal of Surgical Oncology</i> , 2022, 125, 290-298.	0.8	8
598	Treatments and Outcomes in Oligometastatic Soft Tissue Soft Sarcoma – A Single Centre Retrospective Analysis. <i>Anticancer Research</i> , 2021, 41, 5089-5096.	0.5	1
599	Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer. <i>Prostate International</i> , 2021, 9, 113-118.	1.2	24
600	The use of SBRT in the management of oligometastatic gynecological cancer: report of promising results in terms of tolerability and clinical outcomes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3613-3618.	1.2	1
601	Palliative radiotherapy indications during the COVID-19 pandemic and in future complex logistic settings: the NORMALITY model. <i>Radiologia Medica</i> , 2021, 126, 1619-1656.	4.7	33
602	Classifying Oligometastatic Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 4822.	1.7	8
603	Trends in Diagnosis and Treatment of Metastatic Cancer in the United States. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 572-579.	0.6	15
604	Membrane translocation and activation of GnRH receptor sensitize prostate cancer cells to radiation. <i>International Journal of Radiation Biology</i> , 2021, 97, 1555-1562.	1.0	3
605	Documento de consenso de la Sociedad Española de Cirugía Torácica (SECT). Seguimiento a largo plazo de los pacientes operados de cáncer de pulmón. <i>Cirugía Española</i> , 2022, 100, 320-328.	0.1	1
606	Interaction Between Modern Radiotherapy and Immunotherapy for Metastatic Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 744679.	1.3	7
607	A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. <i>Journal of Thoracic Oncology</i> , 2022, 17, 130-140.	0.5	49
608	International Multi-institutional Patterns of Contouring Practice and Clinical Target Volume Recommendations for Stereotactic Body Radiation Therapy for Non-Spine Bone Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 351-360.	0.4	8
610	Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma. <i>Practical Radiation Oncology</i> , 2022, 12, e34-e39.	1.1	3
611	Can Polymetastatic Disease Be ARRESTed Using SABR? A Dosimetric Feasibility Study to Inform Development of a Phase 1 Trial. <i>Advances in Radiation Oncology</i> , 2021, 6, 100734.	0.6	4
612	A 25-year perspective on the evolution of radiation treatment of urologic cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 577-581.	0.8	0

#	ARTICLE	IF	CITATIONS
613	Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies. <i>Cancers</i> , 2021, 13, 4893.	1.7	19
614	Stereotactic and Hypofractionated Radiotherapy Associated With Immune Checkpoint Inhibitor Drugs: Analysis of Local Control, Toxicity, and Outcome in a Single Research Centre Case Study. <i>Anticancer Research</i> , 2021, 41, 5107-5116.	0.5	1
615	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. <i>European Urology</i> , 2021, 80, 374-382.	0.9	49
616	Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective. <i>Radiographics</i> , 2021, 41, 1387-1407.	1.4	30
617	Prostate cancer. <i>Lancet, The</i> , 2021, 398, 1075-1090.	6.3	240
618	Intracranial Treatment in Melanoma Patients with Brain Metastasis Is Associated with Improved Survival in the Era of Immunotherapy and Anti-BRAF Therapy. <i>Cancers</i> , 2021, 13, 4493.	1.7	2
619	The Epidemiology of Lung Metastases. <i>Frontiers in Medicine</i> , 2021, 8, 723396.	1.2	17
620	An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation. <i>Radiotherapy and Oncology</i> , 2021, 164, 104-114.	0.3	10
621	Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery. <i>Oral Oncology</i> , 2021, 121, 105509.	0.8	8
622	OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer. <i>European Urology</i> , 2021, 80, 405-414.	0.9	48
623	A Two-Headed Heated Debate. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 310.	0.4	0
624	Renal atrophy following gated delivery of stereotactic ablative radiotherapy to adrenal metastases. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 20, 1-4.	1.2	1
625	Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumours Treated by Intensity-Modulated Radiotherapy-Based Stereotactic Ablative Body Radiotherapy With Homogenous Dose Prescription. <i>Clinical Oncology</i> , 2021, 33, 627-637.	0.6	9
626	Whole-body MRI: a practical guide for imaging patients with malignant bone disease. <i>Clinical Radiology</i> , 2021, 76, 715-727.	0.5	11
627	Impact of daily plan adaptation on organ-at-risk normal tissue complication probability for adrenal lesions undergoing stereotactic ablative radiation therapy. <i>Radiotherapy and Oncology</i> , 2021, 163, 14-20.	0.3	10
629	Early repeat resection of liver metastases from colorectal cancer may not be justified without controlled trial evidence. <i>Cancer Epidemiology</i> , 2021, 74, 101981.	0.8	0
630	Head and neck proton therapy in France: A missed opportunity or a challenge in front of us?. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021, 25, 537-544.	0.6	0
631	Markerless 3D tumor tracking during single-fraction free-breathing 10MV flattening-filter-free stereotactic lung radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 164, 6-12.	0.3	8

#	ARTICLE	IF	CITATIONS
632	Esophageal-meningeal fistula after anterior cervical corpectomy, stereotactic body radiation therapy (SBRT), and bevacizumab-containing systemic therapy for metastatic epidural spinal cord compression (MESCC). <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2021, 26, 101343.	0.2	1
633	Metastases From Lung Cancer. , 2022, , 785-792.		0
634	Role of radiation therapy in patients with bone metastasis. , 2022, , 909-920.		0
635	Systemic Therapy Improvements Will Render Locoregional Treatments Obsolete for Patients with Cancer with Liver Metastases. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 189-204.	0.6	0
636	Practice patterns for postoperative radiation therapy in patients with metastases to the long bones: a survey of the Japanese Radiation Oncology Study Group. <i>Journal of Radiation Research</i> , 2021, 62, 356-363.	0.8	3
637	Successful treatment of synchronous chemoresistant pulmonary metastasis from pleomorphic rhabdomyosarcoma with stereotaxic body radiation therapy: A case report and a review of the literature.. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100282.	0.7	3
638	Image-Guided Brachytherapy in Oligometastasis: Criteria for Patient Selection from an Oncological Perspective. , 2021, , 75-89.		0
639	Should stereotactic ablative body radiotherapy be the standard of care in oligometastatic cancer?. <i>Lancet Oncology, The</i> , 2021, 22, 6-8.	5.1	5
640	Targeting metastatic cancer. <i>Nature Medicine</i> , 2021, 27, 34-44.	15.2	447
641	Metastatic Urothelial Cancer: a rapidly changing treatment landscape. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110473.	1.4	19
642	The role of immunotherapy in combination with oligometastasis-directed therapy: a narrative review. <i>Annals of Palliative Medicine</i> , 2021, 10, 34-34.	0.5	3
643	Synergy between early-incorporation immunotherapy and extracranial radiotherapy in metastatic non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 261-273.	1.3	0
644	The fallacy of large survival gains from lung metastasectomy in colorectal cancer. <i>Lancet, The</i> , 2021, 397, 97-98.	6.3	3
645	Prognostic Factors Associated With Surviving Less Than 3 Months vs Greater Than 3 Years Specific to Spine Stereotactic Body Radiotherapy and Late Adverse Events. <i>Neurosurgery</i> , 2021, 88, 971-979.	0.6	13
646	Artificial intelligence in image-guided radiotherapy: a review of treatment target localization. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 4881-4894.	1.1	13
647	Outcomes of Stereotactic Body Radiotherapy for Metastatic Colorectal Cancer With Oligometastases, Oligoprogression, or Local Control of Dominant Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 595781.	1.3	7
648	Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. <i>Lancet Oncology, The</i> , 2021, 22, 98-106.	5.1	147
649	OUP accepted manuscript. <i>Japanese Journal of Clinical Oncology</i> , 2021, , .	0.6	1

#	ARTICLE	IF	CITATIONS
650	Treating Oligometastatic Disease With SABR: More Than Just a Numbers Game?. International Journal of Radiation Oncology Biology Physics, 2020, 107, 257-260.	0.4	8
651	Combining Immunotherapy with Radiation Therapy in Nonâ€“Small Cell Lung Cancer. Thoracic Surgery Clinics, 2020, 30, 221-239.	0.4	25
652	Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: Initial outcomes. Technical Innovations and Patient Support in Radiation Oncology, 2020, 13, 24-30.	0.6	9
653	Points to consider regarding the SABR-COMET trial. Lancet, The, 2020, 395, e19.	6.3	5
655	A Novel Staging System for De Novo Metastatic Breast Cancer Refines Prognostic Estimates. Annals of Surgery, 2020, Publish Ahead of Print, .	2.1	15
658	Metastatic salivary gland carcinoma: A role for stereotactic body radiation therapy? A study of AIOâ€“Head and Neck working group. Oral Diseases, 2022, 28, 345-351.	1.5	7
659	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer, 2021, 31, 12-39.	1.2	859
660	Construction of Radiation Surviving/Resistant Lung Cancer Cell Lines with Equidifferent Gradient Dose Irradiation. Dose-Response, 2020, 18, 155932582098242.	0.7	6
661	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2020, 38, 1081.	0.8	101
662	Radiotherapy in lung cancer: Current and future role. Sisli Etfal Hastanesi Tip Bulteni, 2019, 53, 353-360.	0.1	6
663	Evidence for Early Stage Anti-Tumor Immunity Elicited by Spatially Fractionated Radiotherapy-Immunotherapy Combinations. Radiation Research, 2020, 194, 688-697.	0.7	29
664	Stereotactic body radiotherapy for oligometastatic renal cell carcinomaâ€“are we ready to roll?. Annals of Translational Medicine, 2019, 7, S180-S180.	0.7	1
665	SABR-COMET: a new paradigm of care lights up the twilight of metastatic disease. Annals of Translational Medicine, 2019, 7, 615-615.	0.7	4
666	Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news. Ecanermedicalscience, 2020, 14, 1036.	0.6	5
667	Shifting the Immune-Suppressive to Predominant Immune-Stimulatory Radiation Effects by SBRT-Partial Tumor Irradiation Targeting Hypoxic Segment (SBRT-PATHY). Cancers, 2021, 13, 50.	1.7	24
668	Update on Systemic Therapy for Advanced Soft-Tissue Sarcoma. Current Oncology, 2020, 27, 25-33.	0.9	19
669	Local ablative radiotherapy for oligometastatic non-small cell lung cancer. Radiation Oncology Journal, 2019, 37, 149-155.	0.7	12
670	GOECP/SEOR clinical recommendations for lung cancer radiotherapy during the COVID-19 pandemic. World Journal of Clinical Oncology, 2020, 11, 510-527.	0.9	16

#	ARTICLE	IF	CITATIONS
671	Safety of Stereotactic Body Radiation Therapy for Seven Ipsilateral Lung lesions. <i>Cureus</i> , 2020, 12, e8759.	0.2	1
672	Stereotactic Body Radiation Therapy for Recurrent, Isolated Hepatocellular Carcinoma Lymph Node Metastasis With or Without Prior Liver Transplantation. <i>Cureus</i> , 2020, 12, e9988.	0.2	3
673	CXC chemokine receptor 4 (CXCR4) targeted gold nanoparticles potentially enhance radiotherapy outcomes in breast cancer. <i>Nanoscale</i> , 2021, 13, 19056-19065.	2.8	7
675	National Quality Measure Compliance for Palliative Bone Radiation Among Patients With Metastatic Non-Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, , 1-6.	2.3	2
676	Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1131-1139.	0.4	5
677	SEOR&S;BRT-SC stereotactic body radiation therapy consensus guidelines for non-spine bone metastasis. <i>Clinical and Translational Oncology</i> , 2022, 24, 215-226.	1.2	5
678	Stereotactic Body Radiotherapy for Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 553-558.	0.6	2
679	Volumetric burden of metastatic lesions drives outcomes in patients with extracranial oligometastatic disease. <i>Cancer Medicine</i> , 2021, 10, 8091-8099.	1.3	4
681	Impact of 18F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy. <i>Nuclear Medicine Communications</i> , 2022, 43, 201-211.	0.5	2
683	Personalized Treatment Selection Leads to Low Rates of Local Salvage Therapy for Bone Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 99-105.	0.4	3
684	Reirradiation With Stereotactic Radiosurgery After Local or Marginal Recurrence of Brain Metastases From Previous Radiosurgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 726-734.	0.4	24
685	Should We be Offering Our Patients With Oligometastases Stereotactic Ablative Body Radiotherapy?. <i>Clinical Oncology</i> , 2021, 33, 747-748.	0.6	3
686	Oligometastatic Disease Detection with 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact. <i>Cancers</i> , 2021, 13, 4982.	1.7	12
687	Optimal Treatment for Patients with Oligometastatic Prostate Cancer. <i>Urologia Internationalis</i> , 2022, 106, 217-226.	0.6	5
688	Stereotactic body radiation therapy for oligometastatic renal cell carcinoma: improving outcomes in an otherwise radioresistant malignancy. <i>Annals of Translational Medicine</i> , 2019, 7, S98-S98.	0.7	0
689	Expanding the knowledge of oligometastatic disease&quot;but uncertainties remain significant. <i>Journal of Thoracic Disease</i> , 2019, 11, S2008-S2011.	0.6	0
695	Evolving Management of Oligometastatic Disease. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 60-61.	0.6	0
697	Modern evidence and future prospects of external body radiation therapy for lung oligometastases of breast cancer. <i>Translational Cancer Research</i> , 2020, 9, 5077-5086.	0.4	2

#	ARTICLE	IF	CITATIONS
699	Oligometastases: history and future vision of breast cancer. <i>Translational Cancer Research</i> , 2020, 9, 5028-5031.	0.4	3
701	Lung-Derived Selectins Enhance Metastatic Behavior of Triple Negative Breast Cancer Cells. <i>Biomedicines</i> , 2021, 9, 1580.	1.4	5
702	Characteristics of stereotactic radiotherapy clinical trials registered on ClinicalTrials.gov. <i>Translational Cancer Research</i> , 2021, 10, 4316-4326.	0.4	0
703	Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11621.	1.8	13
704	Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1732-1739.	5.1	84
705	Stereotactic Body Radiation Therapy for Oligometastatic Breast Cancer: A Retrospective Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 736690.	1.3	6
706	Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease. <i>Clinical Oncology</i> , 2021, , .	0.6	7
707	Survival Effects of Radiotherapy on Patients Newly Diagnosed with Distant Metastatic Nasopharyngeal Carcinoma in Non-High-Incidence Areas. <i>Cancer Management and Research</i> , 2021, Volume 13, 8169-8178.	0.9	1
708	Stereotactic body radiation therapy: A good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study. <i>World Journal of Clinical Oncology</i> , 2020, 11, 983-989.	0.9	3
709	Editorial: The Evolving Landscape of Stereotactic Body Radiation Therapy for the Management of Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 627686.	1.3	0
710	Stereotactic body radiotherapy with a single isocentre for multiple pulmonary metastases. <i>BJR   case Reports</i> , 2020, 6, 20190121.	0.1	5
711	Role of Cytoreductive Radical Prostatectomy in the Treatment of Metastatic Prostate Cancer. <i>The Korean Journal of Urological Oncology</i> , 2020, 18, 161-169.	0.1	0
712	Oligometastatic disease. , 2022, , 181-182.		0
713	Pulmonary metastasectomy for CRC. , 2022, , 343-353.		0
714	Radiotherapy (stereotactic body radiotherapy) for oligometastatic disease. , 2022, , 421-427.		0
715	Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. <i>Saudi Journal of Gastroenterology</i> , 2020, 26, 1.	0.5	13
716	Does Local Therapy for Oligometastatic Disease in Lung Cancer Patients Improve Survival?. <i>Difficult Decisions in Surgery: an Evidence-based Approach</i> , 2020, , 267-277.	0.0	0
717	Commentary: Has the Time Finally Arrived for Radiofrequency Ablation to Enter the Game?. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2020, 32, 580-581.	0.4	0

#	ARTICLE	IF	CITATIONS
718	Toxicity Management for Thorax Tumors in Radiation Oncology. , 2020, , 107-169.		0
719	Highlights on the Management of Oligometastatic Disease. Journal of Immunotherapy and Precision Oncology, 2020, 3, 34-44.	0.6	3
720	Development and validation of a clinical prediction-score model for distant metastases in major salivary gland carcinoma. Annals of Oncology, 2020, 31, 295-301.	0.6	6
721	Real-World Treatment Patterns of Lung Cancer in a Resource-Restricted Country: the Experience of Georgia. Health Services Insights, 2021, 14, 117863292110552.	0.6	0
723	The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 582 Td 2021, 38, 527-537.	1.7	14
724	Understanding bias in the medical literature: With reflections on metastasectomy. South African Journal of Oncology, 0, 4, .	0.1	0
725	Radiotherapy in Recurrent and Metastatic Rectal Cancer. , 2021, , 683-691.		0
726	Multidisciplinary management of metastatic spine disease: initial symptom-directed management. Neuro-Oncology Practice, 2020, 7, i33-i44.	1.0	1
727	The importance of multidisciplinary care for spine metastases: initial tumor management. Neuro-Oncology Practice, 2020, 7, i25-i32.	1.0	1
728	Trends in Primary Surgical Resection and Chemotherapy for Metastatic Colorectal Cancer, 2000-2016. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 850-856.	0.6	2
730	Public interest in stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) in the United States. Journal of Radiosurgery and SBRT, 2020, 6, 311-315.	0.2	1
731	Stereotactic body radiation therapy (SBRT) for metastatic renal cell carcinoma: A multi-institutional experience. Journal of Radiosurgery and SBRT, 2020, 7, 29-37.	0.2	1
732	One step too far in the right direction: The Society for Translational Medicine 2019 consensus on postoperative management of EGFR-mutant lung cancer. Journal of Thoracic Disease, 2020, 12, 5046-5049.	0.6	0
733	Management of Oligometastatic Prostate Cancer. Applied Radiation Oncology, 2020, 9, 6-10.	0.5	3
734	New Potential Options for SBRT in Pancreatic Cancer. , 2021, 4, 41-50.		0
735	The Efficacy of Radiotherapy in the Treatment of Hepatocellular Carcinoma with Distant Organ Metastasis. Journal of Oncology, 2021, 2021, 1-10.	0.6	5
736	Transfer learning for fluence map prediction in adrenal stereotactic body radiation therapy. Physics in Medicine and Biology, 2021, 66, .	1.6	5
737	Local Treatments in the Unresectable Patient with Colorectal Cancer Metastasis: A Review from the Point of View of the Medical Oncologist. Cancers, 2021, 13, 5938.	1.7	11

#	ARTICLE	IF	CITATIONS
738	Proton Radiotherapy for Patients With Oligometastatic Breast Cancer Involving the Sternum. <i>International Journal of Particle Therapy</i> , 2022, 8, 66-71.	0.9	4
739	Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 5773.	1.7	0
740	Definitive Chemoradiotherapy Results in Synchronous Oligometastatic Non-small Cell Lung Cancer Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, Publish Ahead of Print, .	0.6	1
743	Oligometastatic Disease in Context of the Radiation Oncology Alternative Payment Model: Implications for Local Consolidative Therapy. <i>JCO Oncology Practice</i> , 2021, 17, 773-776.	1.4	2
744	Treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis. <i>Radiation Oncology</i> , 2021, 16, 222.	1.2	5
745	Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma. <i>Cancer Letters</i> , 2022, 526, 346-351.	3.2	10
746	Thoracic Radiotherapy for Renal Cell Carcinoma Metastases: Local Control for the Management of Lung and Mediastinal Disease in the Modern Era. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 107-113.	0.9	3
747	The Role of Ablative Radiotherapy to Liver Oligometastases from Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 0, , 1.	1.0	0
748	Bibliometric Analysis of the Top-Cited Publications and Research Trends for Stereotactic Body Radiotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 795568.	1.3	8
749	Theoretical derivation and clinical dose-response quantification of a unified multi-activation (UMA) model of cell survival from a logistic equation. <i>BJR Open</i> , 2021, 3, 20210040.	0.4	0
751	Practical Management of Oligometastatic Non-small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 635-641.	0.8	33
752	Managing Central Nervous System Spread of Lung Cancer: The State of the Art. <i>Journal of Clinical Oncology</i> , 2022, 40, 642-660.	0.8	23
753	Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. <i>Annals of Surgical Oncology</i> , 2022, 29, 4583-4592.	0.7	4
754	Radiotherapy and radiosensitization in breast cancer: Molecular targets and clinical applications. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103566.	2.0	8
755	Radiating the prostate bed in relapsed oligometastatic prostate cancer: How comprehensive should we be?. <i>Prostate</i> , 2022, , .	1.2	1
756	Cautioning Against Declaring Success Before the Finish Line. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 376-378.	0.4	1
757	Positron Emission Tomography-Derived Metrics Predict the Probability of Local Relapse After Oligometastasis-Directed Ablative Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2022, 7, 100864.	0.6	1
758	One step too far in the right direction: The Society for Translational Medicine 2019 consensus on postoperative management of EGFR-mutant lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 5046-5049.	0.6	0



#	ARTICLE	IF	CITATIONS
759	Oligometastatic nasopharyngeal cancer: Intent and approach?. , 2021, 1, 6.		0
760	Perceptual omission errors in Positron emission tomography/Computed tomography reporting. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, , .	0.4	1
761	Determining Planning Priorities for SABR for Oligometastatic Disease: A Secondary Analysis of the SABR-COMET Phase II Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2022, 114, 1016-1021.	0.4	8
762	Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. British Journal of Radiology, 2022, 95, 20211088.	1.0	1
763	Development and Assessment of a Predictive Score for Vertebral Compression Fracture After Stereotactic Body Radiation Therapy for Spinal Metastases. JAMA Oncology, 2022, 8, 412.	3.4	21
765	Correcting B0 inhomogeneity-induced distortions in whole-body diffusion MRI of bone. Scientific Reports, 2022, 12, 265.	1.6	5
766	Should We Target Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy?. Journal of the National Cancer Institute, 2023, 115, 605-607.	3.0	2
767	PulMiCC was Not Unsuccessful™ and Stereotactic Ablative Body Radiotherapy is Not Like a Parachute: Comments on the Editorial by Ostler et Al.. Clinical Oncology, 2022, 34, e139.	0.6	0
768	Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Advances in Radiation Oncology, 2022, 7, 100899.	0.6	1
769	First-Line Tyrosine Kinase Inhibitors Combined With Local Consolidative Radiation Therapy for Elderly Patients With Oligometastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations. Frontiers in Oncology, 2022, 12, 766066.	1.3	3
770	The Promise of Metastasis-Directed Therapy for Oligometastatic Prostate Cancer: Going Beneath the Surface with Molecular Imaging. Journal of Nuclear Medicine, 2022, 63, 339-341.	2.8	6
771	Clinical Value of Surveillance 18F-fluorodeoxyglucose PET/CT for Detecting Unsuspected Recurrence or Second Primary Cancer in Non-Small Cell Lung Cancer after Curative Therapy. Cancers, 2022, 14, 632.	1.7	5
772	Targeting the STAT5A/IDO1 Axis Overcomes Radiotherapy Resistance and Reverses Immunosuppressive Tumor Microenvironment in Non-Small Cell Lung Cancer. SSRN Electronic Journal, 0, , .	0.4	0
773	Stereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC). Clinical and Translational Radiation Oncology, 2022, 33, 115-119.	0.9	4
774	Brain metastasis in de novo breast cancer: An updated population-level study from SEER database. Asian Journal of Surgery, 2022, 45, 2259-2267.	0.2	8
775	Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. Prostate Cancer and Prostatic Diseases, 2022, 25, 713-719.	2.0	17
776	Cost-Effectiveness of Treatment Strategies for Spinal Metastases. Practical Radiation Oncology, 2022, 12, 236-244.	1.1	8
777	Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab: A retrospective observational study. Thoracic Cancer, 2022, , .	0.8	6

#	ARTICLE	IF	CITATIONS
778	Local control of stereotactic body radiotherapy with dynamic tumor tracking for lung tumors: a propensity score-matched analysis. Japanese Journal of Clinical Oncology, 2022, , .	0.6	1
779	Radiotherapy for Advanced Prostate Cancer. , 2022, , 197-213.		1
780	Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study. Radiotherapy and Oncology, 2022, 168, 256-264.	0.3	20
781	The Emerging Role of Next-Generation Imaging in Prostate Cancer. Current Oncology Reports, 2022, 24, 33-42.	1.8	7
782	Patterns of the use of advanced radiation therapy techniques for the management of bone metastases and the associated factors in Victoria. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 678-687.	0.9	5
783	Performing SBRT in the Fly-With-Caution Zone: Are We Heeding the Advice of Daedalus?. International Journal of Radiation Oncology Biology Physics, 2022, 112, 586-589.	0.4	5
784	Radiotherapy and newly approved cancer drugs – A quantitative analysis of registered protocols for drugs approved for the treatment of solid tumors. Radiotherapy and Oncology, 2022, 168, 69-74.	0.3	0
785	The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma. Clinical and Translational Oncology, 2022, 24, 1533-1541.	1.2	5
786	Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done. Cancers, 2022, 14, 790.	1.7	22
787	Detection of Recurrence After Thoracic Stereotactic Ablative Radiotherapy Using FDG-PET-CT. Clinical Lung Cancer, 2022, 23, 282-289.	1.1	1
788	Radiotherapy for primary lung cancer. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 231-243.	0.6	8
789	Radiotherapy of bone metastases. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 368-376.	0.6	3
790	Symptomatic radiation pneumonitis after stereotactic body radiotherapy for multiple pulmonary oligometastases or synchronous primary lung cancer. Advances in Radiation Oncology, 2022, , 100911.	0.6	0
791	The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature. Frontiers in Oncology, 2022, 12, 797157.	1.3	1
792	Curative intent Stereotactic Ablative Radiation Therapy (SABR) for treatment of lung oligometastases from head and neck squamous cell carcinoma (HNSCC): a multi-institutional retrospective study. British Journal of Radiology, 2022, 95, 20210033.	1.0	5
793	Hypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions. Advances in Radiation Oncology, 2022, 7, 100913.	0.6	4
794	Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. European Journal of Cancer, 2022, 164, 18-29.	1.3	27
795	Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns. Journal of Nuclear Medicine, 2021, 62, 12S-22S.	2.8	14

#	ARTICLE	IF	CITATIONS
796	Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210803.	0.6	2
797	Treatment outcomes of stereotactic ablative body radiotherapy on oligometastases from colorectal cancer: early results of a single institution service evaluation. <i>BJR  Open</i> , 2022, 4, .	0.4	0
798	Performance Evaluation of Deformable Image Registration Algorithms Using Computed Tomography of Multiple Lung Metastases. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382210784.	0.8	2
799	Analysis of online plan adaptation for 1.5T magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT) of prostate cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 841-850.	1.2	2
800	The Role of MRI-Guided Radiotherapy for Soft Tissue Sarcomas. <i>Journal of Clinical Medicine</i> , 2022, 11, 1042.	1.0	1
801	Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 579-579.	1.2	1
802	Oligoscore: a clinical score to predict overall survival in patients with oligometastatic disease treated with stereotactic body radiotherapy. <i>Acta Oncol</i> , 2022, 61, 553-559.	0.8	2
803	Stereotactic Body Radiation Therapy in Patients with Oligometastatic Disease: Clinical State of the Art and Perspectives. <i>Cancers</i> , 2022, 14, 1152.	1.7	10
804	Aggressive Local Therapy for Oligometastatic Non-Small Cell Lung Cancer with Resistance to Anti-Cancer Agents: a Case Report. <i>Japanese Journal of Lung Cancer</i> , 2022, 62, 38-43.	0.0	0
805	Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients's selection. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 449-457.	1.7	5
806	Current Surgical Indications for Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 1263.	1.7	23
807	The prognostic value of circulating lymphocyte counts and ABO blood group in lung cancer stereotactic body radiation therapy: a retrospective study. <i>Journal of Thoracic Disease</i> , 2022, 14, 494-506.	0.6	8
808	Single-fraction stereotactic ablative body radiation therapy for primary and metastatic lung tumor: A new paradigm?. <i>World Journal of Clinical Oncology</i> , 2022, 13, 101-115.	0.9	2
809	Improving Survival Prognostication in Patients With Metastatic Cancer Through Clinical Judgment. <i>Anticancer Research</i> , 2022, 42, 1397-1401.	0.5	1
810	Robotic stereotactic body radiotherapy for the management of adrenal gland metastases: a bi-institutional analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1095-1101.	1.2	3
811	Helical tomotherapy for asymptomatic chemotherapy-refractory or -unfit multiple (3 or more) metastases. <i>Reports of Practical Oncology and Radiotherapy</i> , 2022, 27, 125-133.	0.3	0
812	Association between clinical outcomes and local treatment in stage IV non-small cell lung cancer patients with single extrathoracic metastasis. <i>Thoracic Cancer</i> , 2022, 13, 1349-1360.	0.8	4
813	Stereotactic radiotherapy for lung oligometastases. <i>Reports of Practical Oncology and Radiotherapy</i> , 2022, 27, 23-31.	0.3	0

#	ARTICLE	IF	CITATIONS
814	Evaluation of Patient-Reported Outcome Differences by Radiotherapy Techniques for Bone Metastases in A Population-Based Healthcare System. <i>Current Oncology</i> , 2022, 29, 2073-2080.	0.9	1
815	Spine Stereotactic Body Radiotherapy for Prostate Cancer Metastases and the Impact of Hormone Sensitivity Status on Local Control. <i>Neurosurgery</i> , 2022, 90, 743-749.	0.6	6
816	ASO Author Reflections: Role of Local Treatment for Oligometastatic Esophagogastric Cancer. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	2
817	The role of radiotherapy in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 366-371.	1.2	9
818	A Systematic Review and Meta-analysis of Patient Survival and Disease Recurrence Following Percutaneous Ablation of Pulmonary Metastasis. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 1102-1113.	0.9	9
819	Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis. <i>Gynecologic Oncology</i> , 2022, 164, 550-557.	0.6	7
820	Neutrophil-lymphocyte ratio as a prognostic predictor for patients with cancer treated with stereotactic body radiation therapy: A meta-analysis. <i>Molecular and Clinical Oncology</i> , 2022, 16, 98.	0.4	1
821	Role of stereotactic body radiotherapy in gynecologic radiation oncology. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 372-379.	1.2	8
822	Stereotactic radiotherapy for oligometastases in the lymph nodes. <i>Reports of Practical Oncology and Radiotherapy</i> , 2022, 27, 46-51.	0.3	2
823	A simulated comparison of lung tumor target verification using stereoscopic tomosynthesis or radiography. <i>Medical Physics</i> , 2022, , .	1.6	0
824	Irradiation immunity interactions. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 519-535.	0.9	2
825	SEOM-TTCC clinical guideline in nasopharynx cancer (2021). <i>Clinical and Translational Oncology</i> , 2022, 24, 670-680.	1.2	8
826	Stereotactic Radiotherapy for Lesions Detected via 68Ga-Prostate-specific Membrane Antigen and 18F-Fluorodexyglucose Positron Emission Tomography/Computed Tomography in Patients with Nonmetastatic Prostate Cancer with Early Prostate-specific Antigen Progression on Androgen Deprivation Therapy: A Prospective Single-center Study. <i>European Urology Oncology</i> , 2022, 5, 420-427.	2.6	12
827	Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case-Control Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 4873-4884.	0.7	5
828	Surgery for pulmonary oligometastasis: the good, the bad and the ugly. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, , .	0.6	0
829	Improving the Education of Radiation Oncology Professionals in Geriatric Oncology: Where Are We and Where Should We Be?. <i>Seminars in Radiation Oncology</i> , 2022, 32, 109-114.	1.0	2
830	The Role of Ablative Radiotherapy in Older Adults With Limited Metastatic Disease. <i>Seminars in Radiation Oncology</i> , 2022, 32, 135-141.	1.0	2
831	Acute and Late Esophageal Toxicity After SABR to Thoracic Tumors Near or Abutting the Esophagus. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1144-1153.	0.4	2

#	ARTICLE	IF	CITATIONS
832	Stereotactic body radiotherapy for spinal oligometastases: a review on patient selection and the optimal methodology. <i>Japanese Journal of Radiology</i> , 2022, 40, 1017-1023.	1.0	5
833	Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy. <i>Neoplasia</i> , 2022, 27, 100782.	2.3	1
834	Stereotactic Ablative Radiotherapy for Oligometastatic Disease: Great Enthusiasm but Scant Evidence. <i>Clinical Oncology</i> , 2022, 34, 313-317.	0.6	3
835	UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy. <i>Clinical Oncology</i> , 2022, 34, 288-300.	0.6	36
836	The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy. <i>Frontiers in Oncology</i> , 2021, 11, 799957.	1.3	9
837	Evaluation of patterns of progression on poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer: a cross-sectional study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 153-158.	1.2	2
838	Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 4368-4379.	1.3	15
839	Repetitive Painting (REPEAT) Irradiation in Stereotactic Radiotherapy Using Helical Tomotherapy. <i>In Vivo</i> , 2022, 36, 330-335.	0.6	0
841	Efficacy and Safety of Local Radiotherapy to All Oligometastatic Sites in Elderly Patients with Metachronous Oligometastatic Cancers After Initial Treatment for the Primary Tumor. <i>Cancer Management and Research</i> , 2021, Volume 13, 9247-9259.	0.9	3
842	Interstitial High-Dose-Rate Brachytherapy of Liver Metastases in Oligometastatic Patients. <i>Cancers</i> , 2021, 13, 6250.	1.7	6
843	A Promising Treatment Strategy for Lung Cancer: A Combination of Radiotherapy and Immunotherapy. <i>Cancers</i> , 2022, 14, 203.	1.7	7
844	Outcomes of SBRT for lung oligo-recurrence of non-small cell lung cancer: a retrospective analysis. <i>Journal of Radiation Research</i> , 2022, 63, 272-280.	0.8	3
846	Radiotherapy on-chip: Microfluidics for Translational Radiation Oncology. <i>Lab on A Chip</i> , 2022, , .	3.1	5
847	Utility of Biology-Guided Radiotherapy to De Novo Metastases Diagnosed During Staging of High-Risk Biopsy-Proven Prostate Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 854589.	1.3	5
848	Single-fraction 34 Gy Lung Stereotactic Body Radiation Therapy Using Proton Transmission Beams: FLASH-dose Calculations and the Influence of Different Dose-rate Methods and Dose/Dose-rate Thresholds. <i>Advances in Radiation Oncology</i> , 2022, 7, 100954.	0.6	5
849	Radiation Therapy in Older Adults With Cancer: A Critical Modality in Geriatric Oncology. <i>Journal of Clinical Oncology</i> , 2022, 40, 1806-1811.	0.8	7
850	Imaging Biomarkers in Prostate Stereotactic Body Radiotherapy: A Review and Clinical Trial Protocol. <i>Frontiers in Oncology</i> , 2022, 12, 863848.	1.3	1
851	ASO Author Reflections: The Utility of Circulating-Tumor DNA in Selecting Patients for Locoregional, Metastases-Directed Therapies in Oligometastatic Foregut Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	1

#	ARTICLE	IF	CITATIONS
852	Where Do We Stand in the Management of Oligometastatic Prostate Cancer? A Comprehensive Review. <i>Cancers</i> , 2022, 14, 2017.	1.7	6
855	Letter in Response to "Approach to Oligometastatic Cancer in the Elderly Patient". <i>Current Oncology Reports</i> , 2022, , 1.	1.8	0
857	Defining the role of high-dose radiation in oligometastatic & oligorecurrent cervical cancer.. <i>Indian Journal of Medical Research</i> , 2021, 154, 303-318.	0.4	1
858	A multi-institutional analysis of outcomes following stereotactic body radiation therapy for management of metastases from squamous cell carcinomas of the head and neck.. <i>Journal of Radiosurgery and SBRT</i> , 2022, 8, 11-19.	0.2	0
859	Consolidative radiation in partial responders/unresectable/recurrent disease after first-line/salvage chemotherapy in poor-risk nonseminomatous germ cell tumor prolongs survival: A new paradigm?. <i>Journal of Cancer Research and Therapeutics</i> , 2023, 19, 457.	0.3	0
860	Androgen Receptor Gene Pathway Upregulation and Radiation Resistance in Oligometastatic Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4786.	1.8	4
861	Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR). <i>BMC Cancer</i> , 2022, 22, 468.	1.1	0
862	Multi-Institutional Outcomes of Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy With a Median Biologically Effective Dose of 100 Gy10 for Non-bone Oligometastases. <i>Advances in Radiation Oncology</i> , 2022, 7, 100978.	0.6	5
863	Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. <i>Medical Oncology</i> , 2022, 39, 63.	1.2	6
864	Multidisciplinary Treatment of Non-Spine Bone Metastases: Results of a Modified Delphi Consensus Process. <i>Clinical and Translational Radiation Oncology</i> , 2022, 35, 76-83.	0.9	1
865	Repeated Stereotactic Body Radiotherapy for Lung Malignancies: Toxicity Can Be Reduced by Sparing Lung Irradiation. <i>Anticancer Research</i> , 2022, 42, 2701-2709.	0.5	2
866	An International Expert Delphi Consensus to Develop Dedicated Geriatric Radiation Oncology Curriculum Learning Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 934-945.	0.4	4
867	Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer. <i>Clinical Lung Cancer</i> , 2022, 23, e317-e320.	1.1	10
868	Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report. <i>Translational Lung Cancer Research</i> , 2022, 11, 686-696.	1.3	1
869	Oligometastatic Prostate Cancer: A Comparison between Multimodality Treatment vs. Androgen Deprivation Therapy Alone. <i>Cancers</i> , 2022, 14, 2313.	1.7	3
870	Oligometastatic Rectal Adenocarcinoma Treated With Short-Course Radiation Therapy and Chemotherapy With Nonoperative Intent of the Primary for Locoregional Complete Responders. <i>Practical Radiation Oncology</i> , 2022, 12, e406-e414.	1.1	1
871	Bone Uptake in Prostate Cancer Patients. <i>Clinical Nuclear Medicine</i> , 2022, 47, e529-e539.	0.7	9
872	Definitive local therapy to head and neck squamous cell carcinoma with distant metastasis. <i>Laryngoscope Investigative Otolaryngology</i> , 2022, 7, 757-765.	0.6	3

#	ARTICLE	IF	CITATIONS
873	Oligometastasis in breast cancer – current status and treatment options from a radiation oncology perspective. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 601-611.	1.0	11
874	Comparing Outcomes of Oligometastases Treated with Hypofractionated Image-Guided Radiotherapy (HIGRT) with a Simultaneous Integrated Boost (SIB) Technique versus Metastasis Alone: A Multi-Institutional Analysis. <i>Cancers</i> , 2022, 14, 2403.	1.7	1
875	Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radiotherapy (ADOPT): study protocol for a randomised phase III trial. <i>BMC Cancer</i> , 2022, 22, 482.	1.1	8
877	A role of FDG-PET/CT for response evaluation in metastatic breast cancer?. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 520-530.	2.5	19
878	Evaluation of a Dedicated Software – Elements, Spine SRS, Brainlab – for Target Volume Definition in the Treatment of Spinal Bone Metastases With Stereotactic Body Radiotherapy. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	3
879	Local Therapies in Advanced Colorectal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 553-567.	0.9	3
880	First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2022, 22, 50-54.	0.6	7
881	Multi-institutional phase II study on the safety and efficacy of dynamic tumor tracking-stereotactic body radiotherapy for lung tumors. <i>Radiotherapy and Oncology</i> , 2022, 172, 18-22.	0.3	4
882	Identifying nasopharyngeal carcinoma patients with metachronous metastasis sensitive to local treatment: a real-world study Running title: Local treatment of metastatic nasopharyngeal carcinoma. <i>Journal of Biomedical Research</i> , 2022, 36, 1.	0.7	0
883	Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer – Prevalence and Current Clinical Practice. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	3
884	The EA2108 Clinical Trial and Real-World Data: A Cautionary Tale in Stage IV Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	0
885	Stereotactic Body Radiation in Breast Cancer – Definitive, Oligometastatic, and Beyond. <i>Current Breast Cancer Reports</i> , 0, , .	0.5	0
886	Documento de consenso de la Sociedad Española de Cirugía Torácica (SECT). Seguimiento a largo plazo de los pacientes operados de cáncer de pulmón. <i>Cirugía Española (English Edition)</i> , 2022, , .	0.1	1
887	ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases. <i>Radiotherapy and Oncology</i> , 2022, 173, 197-206.	0.3	28
888	Toward Improved Outcomes for Patients With Lung Cancer Globally: The Essential Role of Radiology and Nuclear Medicine. <i>JCO Global Oncology</i> , 2022, , .	0.8	1
890	Combination of SABR With Anti-PD-1 in Oligoprogressive Non-Small Cell Lung Cancer and Melanoma: Results of a Prospective Multicenter Observational Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 655-665.	0.4	15
891	Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective. <i>Journal of Thoracic Oncology</i> , 2022, 17, 961-973.	0.5	9
892	Local thermal ablative therapies for extracranial oligometastatic disease of non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , .	0.7	2

#	ARTICLE	IF	CITATIONS
893	Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 666-675.	0.4	5
894	Combination of OX40 Co-Stimulation, Radiotherapy, and PD-1 Inhibition in a Syngeneic Murine Triple-Negative Breast Cancer Model. <i>Cancers</i> , 2022, 14, 2692.	1.7	11
895	Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.4	4
896	Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 611-616.	0.4	76
897	Planning Trade-offs for SABR in Patients With 4 to 10 Metastases: A Substudy of the SABR-COMET-10 Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 1011-1015.	0.4	5
898	Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 617-626.	0.4	18
899	Construction and Verification of Nomogram Model for Lung Adenocarcinoma With $\geq$ 5 Bone-Only Metastases Basing on Hematology Markers. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
900	Genomic biomarkers to guide precision radiotherapy in prostate cancer. <i>Prostate</i> , 2022, 82, .	1.2	3
901	Health related quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease: A systematic review and individual patient data meta-analysis. <i>Radiotherapy and Oncology</i> , 2022, 173, 163-169.	0.3	6
902	Attitudes and access to resources and strategies to improve quality of radiotherapy among <sc>US</sc> radiation oncologists: A mixed methods study. <i>Journal of Medical Imaging and Radiation Oncology</i> , 0, , .	0.9	2
905	Rates of <sc>MRI</sc> simulator utilisation in a tertiary cancer therapy centre. <i>Journal of Medical Imaging and Radiation Oncology</i> , 0, , .	0.9	1
906	Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study. <i>Radiotherapy and Oncology</i> , 2022, 173, 269-276.	0.3	18
907	Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 587-595.	0.4	10
908	Distant Metastasis Velocity as a Novel Prognostic Score for Overall Survival After Disease Progression Following Stereotactic Body Radiation Therapy for Oligometastatic Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 871-882.	0.4	5
909	Steering decision making by terminology: oligometastatic versus argometastatic. <i>British Journal of Cancer</i> , 0, , .	2.9	4
910	Radiation myelopathy following stereotactic body radiation therapy for spine metastases. <i>Journal of Neuro-Oncology</i> , 2022, 159, 23-31.	1.4	7
911	Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 645-654.	0.4	10
912	A Multimodal Clinical Approach for the Treatment of Bone Metastases in Solid Tumors. <i>Anesthesiology and Pain Medicine</i> , 2022, 12, .	0.5	2



#	ARTICLE	IF	CITATIONS
913	Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for Oligometastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 862-870.	0.4	5
914	Current treatment landscape for oligometastatic non-small cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2022, 13, 485-495.	0.9	1
915	Integrated 18F-FDG PET/CT parameter defines metabolic oligometastatic non-small cell lung cancer. <i>Nuclear Medicine Communications</i> , 0, Publish Ahead of Print, .	0.5	0
917	Oligometastatic Breast Cancer. <i>Seminars in Radiation Oncology</i> , 2022, 32, 282-290.	1.0	4
918	Usefulness of palliative radiotherapy in reducing the frequency of red blood cell transfusion in patients with malignant tumor bleeding. <i>Journal of Cancer Research and Therapeutics</i> , 2022, .	0.3	0
919	Radiation strategy and techniques for metastatic pleural disease from thymic malignancies: extended abstract. <i>Mediastinum</i> , 0, .	0.6	0
920	Stereotactic radiotherapy of oligometastatic disease: a new paradigm for a curative approach. <i>Reports of Practical Oncology and Radiotherapy</i> , 2022, 27, 376-378.	0.3	0
921	Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 910-918.	0.4	11
922	Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719). <i>Radiologia Medica</i> , 2022, 127, 912-918.	4.7	5
923	Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Retrospective Comparison Focusing on Pulmonary Toxicity. <i>Cancers</i> , 2022, 14, 3226.	1.7	3
924	In Silico Trial of Computed Tomography-Guided Stereotactic Adaptive Radiation Therapy (CT-STAR) for the Treatment of Abdominal Oligometastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 1022-1031.	0.4	9
925	Long-Term Outcomes of Patients on a Phase II Prospective Trial of Oligometastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation and External Beam Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 705-710.	0.4	3
927	A case of hepatocellular carcinoma with long-term survival by multidisciplinary treatment for cranial and skeletal muscle metastases. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	1
928	Study Protocol for a Randomised Controlled Trial on Pulmonary Metastasectomy vs. Standard of Care in Colorectal Cancer Patients With ≥3 Lung Metastases (PUCC-Trial). <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
929	Applications of artificial intelligence in stereotactic body radiation therapy. <i>Physics in Medicine and Biology</i> , 2022, 67, 16TR01.	1.6	7
930	A Critical Review of the Role of Local Therapy for Oligometastatic Gastrointestinal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.4	1
931	Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 856-861.	0.4	5
932	Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma. <i>Radiation Oncology</i> , 2022, 17, .	1.2	8

#	ARTICLE	IF	CITATIONS
933	Risk Prediction Model for Synchronous Oligometastatic Non-Small Cell Lung Cancer: Thoracic Radiotherapy May Not Prolong Survival in High-Risk patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
934	The oligometastatic spectrum in the era of improved detection and modern systemic therapy. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 585-599.	12.5	39
935	Patient and Treatment Factors Associated With Improved Local Control and Survival in Oligometastatic Bone Disease: Results From a Large Single-Institution Experience Using Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 747-761.	0.4	8
936	Towards Accurate and Precise Image-Guided Radiotherapy: Clinical Applications of the MR-Linac. <i>Journal of Clinical Medicine</i> , 2022, 11, 4044.	1.0	8
937	Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiation Therapy for Non-Small Cell Lung Cancer. <i>Practical Radiation Oncology</i> , 2023, 13, e35-e44.	1.1	1
938	Importance of Local Ablative Therapies for Lung Metastases in Patients With Colorectal Cancer. <i>Annals of Surgery</i> , 2023, 278, e173-e178.	2.1	3
939	Safety and Tolerability of Metastasis-Directed Radiation Therapy in the Era of Evolving Systemic, Immune, and Targeted Therapies. <i>Advances in Radiation Oncology</i> , 2022, 7, 101022.	0.6	8
940	Salvage (re) radiation in oligometastatic and oligorecurrent cervical cancer.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.4	1
941	Practice changing data and emerging concepts from recent radiation therapy randomised clinical trials. <i>European Journal of Cancer</i> , 2022, 171, 242-258.	1.3	3
942	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer. <i>ESMO Open</i> , 2022, 7, 100518.	2.0	10
944	Locoregional Approaches to Colorectal Liver Metastasis – Radiation Options. , 2023, , 211-231.		0
945	The role of hepatic and pancreatic metastatectomy in the management of metastatic renal cell carcinoma: A systematic review. <i>Surgical Oncology</i> , 2022, 44, 101819.	0.8	2
946	Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
947	Patient Reported and Clinical Outcomes from 5 Fraction SBRT for Oligometastases – a Prospective Single Institution Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.4	0
948	A –Hybrid–™ Radiotherapy Regimen Designed for Immunomodulation: Combining High-Dose Radiotherapy with Low-Dose Radiotherapy. <i>Cancers</i> , 2022, 14, 3505.	1.7	3
949	Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1164-1170.	1.2	12
950	Interobserver Variability of Gross Tumor Volume Delineation for Colorectal Liver Metastases Using Computed Tomography and Magnetic Resonance Imaging. <i>Advances in Radiation Oncology</i> , 2023, 8, 101020.	0.6	1
951	A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and <i>In Situ</i> Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4392-4401.	3.2	13

#	ARTICLE	IF	CITATIONS
952	The Impact of Disease Progression on Health-Related Quality of Life Outcomes in Patients With Oligometastatic Disease at 12 Months Post Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 989-999.	0.4	2
953	Radiation Therapy in Oligometastatic Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 684-692.	0.4	7
954	Technical feasibility of online adaptive stereotactic treatments in the abdomen on a robotic radiosurgery system. <i>Physics and Imaging in Radiation Oncology</i> , 2022, 23, 103-108.	1.2	1
955	MRI-guided Radiotherapy (MRgRT) for Treatment of Oligometastases: Review of Clinical Applications and Challenges. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 950-967.	0.4	10
956	Imaging-Based Prevalence of Oligometastatic Disease: A Single-Center Cross-Sectional Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 596-602.	0.4	12
957	Ablative Radiation Therapy in Oligometastatic Pancreatic Cancer to Delay Polyprogression, Limit Chemotherapy, and Improve Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 792-802.	0.4	9
958	Outcome of lung oligometastatic patients treated with stereotactic body irradiation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
959	Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer. <i>Breast</i> , 2022, 66, 145-156.	0.9	3
960	Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study. <i>Clinical and Translational Radiation Oncology</i> , 2022, 37, 109-115.	0.9	2
961	Patterns of care in oligometastatic disease: the clinicians' perspective. <i>Acta Oncologica</i> , 2022, 61, 1148-1151.	0.8	0
962	Local Consolidative Therapy for Oligometastatic Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3977.	1.7	3
963	Lung stereotactic radiation therapy: Intercomparison of irradiation devices in terms of outcome and predictive factors. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2022, , .	0.6	2
964	Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases: a systematic meta-analysis. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	4
965	Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer. <i>European Urology Oncology</i> , 2022, 5, 695-703.	2.6	17
966	Consensus statement for metastatic surveillance of uveal melanoma in Scotland. <i>Eye</i> , 0, , .	1.1	1
967	Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 762-770.	0.4	13
968	Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancer. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2022, 26, 1045-1053.	0.6	2
969	Oligometastatic Head and Neck Cancer: Challenges and Perspectives. <i>Cancers</i> , 2022, 14, 3894.	1.7	9

#	ARTICLE	IF	CITATIONS
970	Older adults and the unique role of the radiation therapist: Future directions for improving geriatric oncology training and education. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2022, 23, 21-26.	0.6	1
971	Ways to improve breast cancer patients' management and clinical outcome: The 2020 Assisi Think Tank Meeting. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 177, 103774.	2.0	1
972	Stereotactic body radiation therapy for spine and non-spine bone metastases. GETUG (french society of) Tj ETQq0 0 0 rgBT /Overlock 10 survey. <i>Clinical and Translational Radiation Oncology</i> , 2022, 37, 33-40.	0.9	0
973	Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions. <i>Breast Cancer Research and Treatment</i> , 2022, 196, 215-220.	1.1	1
974	Nanoradiosensitizer with good tissue penetration and enhances oral cancer radiotherapeutic effect. <i>Biomaterials</i> , 2022, 289, 121769.	5.7	3
976	Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?. <i>Cancer Treatment Reviews</i> , 2022, 110, 102462.	3.4	6
977	Treatment of Second Lung Cancers. <i>Medical Radiology</i> , 2022, , .	0.0	0
978	Oligometastatic and Oligoprogression Disease. , 2022, , 393-400.		0
979	Novel Multidisciplinary Paradigms: Surgery/Radiation, Immunotherapy, Organ Preservation. , 2022, , 13-23.		0
980	Changing treatment paradigms of radiotherapy for the treatment of lung cancer. <i>Journal of Radiation and Cancer Research</i> , 2022, .	0.0	0
981	Radiotherapy and Immunotherapy for Head and Neck Cancer. , 2022, , 91-113.		0
982	Application of real-time MRI-guided linear accelerator in stereotactic ablative body radiotherapy for non-small cell lung cancer: one step forward to precise targeting. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3215-3223.	1.2	1
984	Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 693-704.	0.4	11
985	2022 American Society of Clinical Oncology (ASCO): Meeting highlights. <i>Canadian Urological Association Journal</i> , 2022, 16, E499-504.	0.3	0
986	Practice Patterns and Perspectives on Stereotactic Body Radiation Therapy for the Metastatic Spine From Lower- and Middle-Income Countries. <i>JCO Global Oncology</i> , 2022, , .	0.8	3
987	The Current Role of Stereotactic Body Radiation Therapy (SBRT) in Hepatocellular Carcinoma (HCC). <i>Cancers</i> , 2022, 14, 4383.	1.7	15
988	Local control after palliative external beam radiotherapy for bone metastases in patients with favorable prognosis. <i>Molecular and Clinical Oncology</i> , 2022, 17, .	0.4	1
989	Fifty-year history of the evolution of spinal metastatic disease management. <i>Journal of Surgical Oncology</i> , 2022, 126, 913-920.	0.8	0

#	ARTICLE	IF	CITATIONS
990	Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 1644.	3.4	21
991	Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 196, 341-348.	1.1	7
992	Feasibility, Method and Early Outcome of Image-Guided Volumetric Modulated Arc Radiosurgery Followed by Resection for AJCC Stage IIA-III B High-Risk Large Intraocular Melanoma. <i>Cancers</i> , 2022, 14, 4729.	1.7	1
993	Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer. <i>European Journal of Surgical Oncology</i> , 2023, 49, 21-28.	0.5	10
994	Clinical Outcomes of Stereotactic Ablative Radiotherapy for All Stages of Non-Small Cell Lung Cancer; Definitive versus Consolidative. <i>Medicina (Lithuania)</i> , 2022, 58, 1304.	0.8	0
995	Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	1
996	The Management of Oligometastases in Non-small Cell Lung Cancer – is Stereotactic Ablative Radiotherapy now Standard of Care?. <i>Clinical Oncology</i> , 2022, , .	0.6	2
997	Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage <sc>III</sc> non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 3152-3161.	0.8	11
998	Systemic Therapy Combined with Locoregional Therapy Improved Survival in Oligometastatic Breast Cancer: A Single-Center Retrospective Cohort Study. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	1
999	Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With <i>ALK</i>/<i>ROS1</i>/<i>RET</i>-Rearranged Lung Cancers. <i>JCO Precision Oncology</i> , 2022, , .	1.5	3
1000	Translational and Clinical Approach to Combining Immunotherapy with Radiotherapy in the Treatment of Head and Neck Cancer. , 2022, , .		0
1001	Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211331.	1.4	7
1002	Radiation Therapy for Oligometastatic Sarcomas. <i>Practical Guides in Radiation Oncology</i> , 2022, , 77-110.	0.0	0
1003	Stereotactic Body Radiation Therapy (SBRT) Re-irradiation to an Isolated Oligo-Recurrent Lymph Node with Direct Positron Emission Tomography/Computed Tomography Planning: A Case Report. <i>International Journal of Surgery Oncology</i> , 2022, 7, 90-101.	0.2	0
1004	Progression-Free Survival or Failure of Local Treatment Strategy: End Points for Trials Testing Stereotactic Body Radiotherapy. <i>Journal of Clinical Oncology</i> , 2023, 41, 938-939.	0.8	2
1005	The potential of biology-guided radiation therapy in thoracic cancer: A preliminary treatment planning study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1006	Dosimetric Evaluation of the Inter-Fraction Motion of Organs at Risk in SBRT for Nodal Oligometastatic Prostate Cancer. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 10949.	1.3	0
1007	Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy. <i>Biomedicines</i> , 2022, 10, 2481.	1.4	7

#	ARTICLE	IF	CITATIONS
1009	Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CT. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
1011	Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients. <i>Current Oncology</i> , 2022, 29, 7832-7841.	0.9	4
1012	Results from the AAPM Task Group 324 respiratory motion management in radiation oncology survey. <i>Journal of Applied Clinical Medical Physics</i> , 2022, 23, .	0.8	10
1013	Dose-Escalated 2-Fraction Spine Stereotactic Body Radiation Therapy: 28 Gy Versus 24 Gy in 2 Daily Fractions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 686-695.	0.4	15
1014	Oligometastases: Emerging Evidence. <i>Journal of Clinical Oncology</i> , 2022, 40, 4250-4260.	0.8	15
1015	Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 849-855.	0.4	5
1018	Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 561-570.	0.4	1
1019	From Idea to Clinical Practice: A Brief History of Oligometastatic Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 576-580.	0.4	1
1020	Basic principles in gynecologic radiotherapy. , 2023, , 624-645.e4.		0
1021	Stereotactic Ablative Radiation Therapy for Colorectal Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2023, 22, 120-128.	1.0	2
1022	Case 35-2022: A 60-Year-Old Man with Progressive Dyspnea, Neck Swelling, and a Lung Mass. <i>New England Journal of Medicine</i> , 2022, 387, 1889-1896.	13.9	1
1023	Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes. <i>Expert Review of Hematology</i> , 2022, 15, 1023-1030.	1.0	4
1024	The Effect of immunotherapy on oligometastatic non-small cell lung cancer patients by sites of metastasis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1025	French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance. <i>Progres En Urologie</i> , 2022, 32, 1373-1419.	0.3	5
1027	Oligometastases in head and neck squamous cell carcinoma patients. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 1-3.	1.1	1
1029	Toxicity and Efficacy of Multitarget Thoracic Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 897-905.	0.4	1
1030	Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e93-e103.	0.9	1
1031	Flipping the Null: Lessons From Breast Cancer and Recalibrating Expectations in Oligometastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 840-842.	0.4	0

#	ARTICLE	IF	CITATIONS
1032	Recognition of and treatment recommendations for oligometastatic disease in multidisciplinary tumor boards. <i>Clinical and Translational Radiation Oncology</i> , 2023, 38, 123-129.	0.9	2
1033	Oligometastatic Disease: Basic Aspects and Clinical Results in NSCLC. <i>Medical Radiology</i> , 2022, , .	0.0	0
1034	Rationale for the MR-linac. <i>Advances in Magnetic Resonance Technology and Applications</i> , 2023, , 1-4.	0.0	0
1035	Clinical and practical applications of radiation therapy: when should radiation therapy be considered for my patient?. <i>Medicine</i> , 2023, 51, 17-22.	0.2	0
1036	Stereotactic magnetic resonance-guided online adaptive radiotherapy of adrenal metastases combines high ablative doses with optimized sparing of organs at risk. <i>Clinical and Translational Radiation Oncology</i> , 2023, 39, 100567.	0.9	3
1037	Management of patients with advanced prostate cancer in Japan: "real-world"™ consideration of the results from the Advanced Prostate Cancer Consensus Conference. <i>Translational Andrology and Urology</i> , 2022, 11, 1771-1785.	0.6	2
1038	Oligoprogression in non-small cell lung cancer: a narrative review. <i>Journal of Thoracic Disease</i> , 2022, 14, 4998-5011.	0.6	7
1039	Oligometastatic disease: Adrenal, lymph nodes, bone. <i>Advances in Magnetic Resonance Technology and Applications</i> , 2023, , 375-396.	0.0	0
1040	Gynecological tumors. <i>Advances in Magnetic Resonance Technology and Applications</i> , 2023, , 397-445.	0.0	0
1041	ESTRO Breur lecture 2022: Real-time MRI-guided radiotherapy: The next generation standard?. <i>Radiotherapy and Oncology</i> , 2022, 176, 244-248.	0.3	2
1042	Stereotactic Ablative Radiotherapy for Oligometastatic Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 20-04). <i>Cancers</i> , 2022, 14, 5848.	1.7	3
1043	Stereotactic radiosurgery and local control of brain metastases from triple-negative breast cancer. <i>Journal of Neurosurgery</i> , 2022, , 1-7.	0.9	4
1044	Should Stereotactic Ablative Radiotherapy Be Used for Oligometastatic Disease?. , 2022, 1, .		1
1045	Perspective Chapter: Bone Metastases of Solid Tumors. , 0, , .		0
1046	Systemic therapy-based split-course stereotactic body radiation therapy. <i>Precision Radiation Oncology</i> , 2022, 6, 306-320.	0.4	0
1047	Targeting the STAT5A/IDO1 axis overcomes radioresistance and reverses the immunosuppressive tumor microenvironment in NSCLC. <i>International Journal of Oncology</i> , 2022, 62, .	1.4	2
1048	Radiochirurgie und stereotaktische Strahlentherapie. <i>Springer Reference Medizin</i> , 2023, , 1-9.	0.0	0
1049	Efficacy and Failure Patterns of Early SBRT to the Primary Tumor in Advanced EGFR-Mutation-Positive Lung Cancer with EGFR-TKI Treatment: A Prospective, Single Arm, Phase II Study. <i>Life</i> , 2022, 12, 1954.	1.1	1

#	ARTICLE	IF	CITATIONS
1050	Evaluation of 5 Fraction Stereotactic Body Radiation Therapy (SBRT) for Osseous Renal Cell Carcinoma Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 501-505.	0.6	2
1051	Approaches to the Management of Metastatic Adenoid Cystic Carcinoma. <i>Cancers</i> , 2022, 14, 5698.	1.7	11
1052	Optimal Definition of Oligometastasis Showing Survival Benefits of Local Therapies During Tyrosine Kinase Inhibitor Treatment. <i>Cancer Research and Treatment</i> , 0, , .	1.3	0
1053	Volumetric modulated arc therapy ( <sc>VMAT</sc> ) comparison to <sc>3D</sc> â€conformal technique in lung stereotactic ablative radiotherapy ( <sc>SABR</sc> ). <i>Journal of Medical Radiation Sciences</i> , 0, , .	0.8	1
1054	Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. <i>European Urology</i> , 2023, 83, 267-293.	0.9	39
1055	Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors. <i>Oncolimmunology</i> , 2023, 12, .	2.1	7
1056	ICRU REPORT 97: MRI-Guided Radiation Therapy Using MRI-Linear Accelerators. <i>Journal of the ICRU</i> , 2022, 22, 1-100.	6.0	12
1058	The â€œnewâ€ oligometastatic disease state and associated therapies in nonâ€small cell lung cancer: A narrative review. <i>Journal of Surgical Oncology</i> , 2023, 127, 282-287.	0.8	3
1060	SURGICAL TREATMENT AS AN INCREASE IN THE SURVIVAL OF PATIENTS WITH LIVER OLIGOMETASTASIS OF DUCTAL ADENOCARCINOMA OF THE PANCREAS. PATIENT SELECTION CRITERIA. REVIEW. <i>Surgical Practice</i> , 2022, , 48-60.	0.0	0
1061	Local therapy treatment conditions for oligometastatic non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1062	Yttrium-90 Radiation Segmentectomy in Oligometastatic Secondary Hepatic Malignancies. <i>Journal of Vascular and Interventional Radiology</i> , 2023, 34, 362-368.	0.2	3
1063	Top Ten Lessons Learned from Trials in Oligometastatic Cancers. <i>Cancer Research and Treatment</i> , 2023, 55, 5-14.	1.3	5
1064	SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
1065	Difference in failure patterns after stereotactic body radiotherapy for lung cancer according to clinical TÂstage based on 4D computed tomography. <i>Strahlentherapie Und Onkologie</i> , 0, , .	1.0	1
1066	Consolidative highâ€dose thoracic radiotherapy for limited metastatic nonsmall cell lung cancer: Focusing on oligoâ€progressive disease. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , .	0.7	0
1067	Accelerated hypofractionated radiotherapy with 3ÂGy per fraction for central/ultra-central lung tumors: toxicity to mediastinal organs. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	0
1068	Strahlentherapie bei lokoregionÃren Metastasen. <i>Springer Reference Medizin</i> , 2023, , 1-11.	0.0	0
1069	Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	0



#	ARTICLE	IF	CITATIONS
1070	Efficacy and Safety of Stereotactic Body Radiation Therapy for Pediatric Malignancies: The LITE-SABR Systematic Review and Meta-Analysis. <i>Advances in Radiation Oncology</i> , 2023, 8, 101123.	0.6	1
1071	Effect of Immunotherapy and Stereotactic Body Radiation Therapy Sequencing on Local Control and Survival in Patients With Spine Metastases. <i>Advances in Radiation Oncology</i> , 2023, 8, 101179.	0.6	2
1072	Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination. , 2023, 11, e005463.		2
1073	Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer. <i>Cancer Management and Research</i> , 0, Volume 15, 55-65.	0.9	5
1074	Respiratory motion tracking of spine stereotactic radiotherapy in prone position. <i>Journal of Applied Clinical Medical Physics</i> , 0, , .	0.8	1
1075	Thoracic imaging. , 2023, , 179-198.		0
1076	Local control and patient reported outcomes after online MR guided stereotactic body radiotherapy of liver metastases. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1077	Association between radiotherapy and risk of death from cardiovascular diseases in lung and bronchus cancer. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
1078	Five-Fraction Stereotactic Radiotherapy for Brain Metastasesâ€”A Retrospective Analysis. <i>Current Oncology</i> , 2023, 30, 1300-1313.	0.9	4
1079	Stereotactic Body Radiotherapy and Immunotherapy for Older Patients with Oligometastases: A Proposed Paradigm by the International Geriatric Radiotherapy Group. <i>Cancers</i> , 2023, 15, 244.	1.7	3
1080	CT radiomic predictors of local relapse after SBRT for lung oligometastases from colorectal cancer: a single institute pilot study. <i>Strahlentherapie Und Onkologie</i> , 2023, 199, 477-484.	1.0	2
1081	Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes. <i>Breast</i> , 2023, 67, 102-109.	0.9	7
1082	MRI-LINAC: A transformative technology in radiation oncology. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	8
1083	Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
1084	Cervicothoracic junction instrumentation strategies following separation surgery for spinal metastases. <i>Journal of Neurosurgery: Spine</i> , 2023, 38, 473-480.	0.9	3
1085	Surgery in the Setting of Metastatic Breast Cancer. <i>Current Breast Cancer Reports</i> , 0, , .	0.5	0
1086	First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma â€” A real-world experience from Israel. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	5
1087	WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 1095-1101.	0.4	4

#	ARTICLE	IF	CITATIONS
1088	Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?. Expert Review of Anticancer Therapy, 2023, 23, 163-176.	1.1	0
1089	Clinical Outcomes of Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Patients with Lymph Node Metastases from Gynecological Cancers. Journal of Personalized Medicine, 2023, 13, 229.	1.1	0
1090	Hypofractionated Stereotactic Radiation Therapy Dosimetric Tolerances for the Inferior Aspect of the Brachial Plexus: A Systematic Review. International Journal of Radiation Oncology Biology Physics, 2024, 118, 931-943.	0.4	6
1091	Is single fraction the future of stereotactic body radiation therapy (SBRT)? A critical appraisal of the current literature. Clinical and Translational Radiation Oncology, 2023, 39, 100584.	0.9	1
1092	Benign and Malignant Renal Disease. IDKD Springer Series, 2023, , 153-168.	0.8	0
1093	FDG-PET metrics in advanced non-small cell lung cancer (NSCLC): a review and meta-analysis. Clinical and Translational Imaging, 0, , .	1.1	1
1094	Oligometastatic breast cancer to parotid gland with complete response. Breast Disease, 2023, 42, 67-71.	0.4	1
1095	Improvement in radiation techniques for locally advanced cervical cancer during the last two decades. International Journal of Gynecological Cancer, 2023, 33, 1295-1303.	1.2	3
1096	Local interventions for colorectal cancer metastases to liver and lung. Irish Journal of Medical Science, 0, , .	0.8	1
1097	The management of oligometastatic disease in colorectal cancer: Present strategies and future perspectives. Critical Reviews in Oncology/Hematology, 2023, 186, 103990.	2.0	1
1098	Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial. Radiotherapy and Oncology, 2023, 182, 109576.	0.3	6
1099	Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe. European Journal of Cancer, 2023, 185, 28-39.	1.3	11
1100	Management of patients with advanced prostate cancerâ€™ metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European Journal of Cancer, 2023, 185, 178-215.	1.3	26
1101	Planning for the Effect of the SC.24 Trial on Spine Stereotactic Body Radiation Therapy Utilization at a Tertiary Cancer Center. Advances in Radiation Oncology, 2023, 8, 101220.	0.6	1
1102	Is Oligometastatic Cancer Curable? A Survey of Oncologist Perspectives, Decision Making, and Communication. Advances in Radiation Oncology, 2023, 8, 101221.	0.6	1
1104	Prognostic Role of Biologically Active Volume of Disease in Patients With Metastatic Lung Adenocarcinoma. Clinical Lung Cancer, 2023, , .	1.1	0
1105	An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer. Critical Reviews in Oncology/Hematology, 2023, 183, 103916.	2.0	4
1106	Stereotactic body radiation therapy for kidney cancer. Where do we stand?. International Journal of Urology, 2023, 30, 437-445.	0.5	4

#	ARTICLE	IF	CITATIONS
1107	Contemporary Treatment Outcome of Metastases to the Pituitary Gland. <i>World Neurosurgery</i> , 2023, 172, e684-e694.	0.7	1
1108	A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination Therapy for Extending Survival. <i>Gastroenterology Insights</i> , 2023, 14, 38-44.	0.7	2
1109	Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2023, 21, 181-209.	2.3	80
1110	Clinical and pathological characterization of 158 consecutive and unselected oligometastatic breast cancers in a single institution. <i>Breast Cancer Research and Treatment</i> , 2023, 198, 463-474.	1.1	1
1111	Global research trends in palliative care for breast cancer from 2012 to 2022: A scientometric analysis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1112	Magnetic Resonance-Guided Stereotactic Body Radiation Therapy/Hypofractionated Radiation therapy for Metastatic and Primary Central and Ultracentral Lung Lesions. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100488.	0.6	3
1113	The characteristics of oncological clinical trials investigating the synergistic effect of radiotherapy and immune checkpoint inhibitors: a cross-sectional study. <i>Translational Cancer Research</i> , 2023, 12, 558-571.	0.4	0
1114	Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy. <i>European Urology Oncology</i> , 2023, , .	2.6	2
1115	Impact of Postoperative Stereotactic Body Radiation Therapy on Survival of Patients with Spinal Metastases in the Context of Additional Systemic Adjuvant Therapy. <i>World Neurosurgery</i> , 2023, 173, e787-e799.	0.7	0
1116	Is stereotactic body radiotherapy an effective treatment in metastatic lung cancer with oligoprogressive disease?. <i>Acta Oncol3gica</i> , 2023, 62, 298-304.	0.8	0
1117	A Feasibility Study of Functional Lung Volume Preservation during Stereotactic Body Radiotherapy Guided by Gallium-68 Perfusion PET/CT. <i>Cancers</i> , 2023, 15, 1726.	1.7	2
1118	How Stereotactic Radiotherapy Changed the Landscape in Cancer Care. <i>Cancers</i> , 2023, 15, 1734.	1.7	3
1119	Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy. <i>Cancer Imaging</i> , 2023, 23, .	1.2	9
1120	Editorial: Women in radiation oncology: 2021. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1121	Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311614.	1.4	1
1122	Established and new horizons in radiotherapy for breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311614.	1.4	1
1123	Pain and Interventions in Stage IV Non-Small Cell Lung Cancer: A Province-Wide Analysis. <i>Current Oncology</i> , 2023, 30, 3461-3472.	0.9	1
1124	Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapyâ€”A Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5858.	1.8	4

#	ARTICLE	IF	CITATIONS
1125	Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives. <i>Cancers</i> , 2023, 15, 1827.	1.7	5
1126	Comparison of Hormone-Sensitive Oligorecurrent Prostate Cancer Patients Based on Routine Use of Choline and/or PSMA PET/CT to Guide Metastasis-Directed Therapy. <i>Cancers</i> , 2023, 15, 1898.	1.7	2
1127	Radiation therapy for vulvar cancer: consensus guidelines of the GINECOR working group of the Spanish Society of Radiation Oncology. Part 1: clinical recommendations. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	1
1128	Stereotactic Body Radiation Therapy in the Management of Recurrent and/or Oligometastatic Head and Neck Cancer. , 2023, , 229-236.		0
1129	Stereotactic Body Radiation Therapy for Spinal Metastases: Benefits and Limitations. <i>Seminars in Radiation Oncology</i> , 2023, 33, 159-171.	1.0	12
1130	Development and validation of a unifying pre-treatment decision tool for intracranial and extracranial metastasis-directed radiotherapy. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1131	Radiotherapy for Lung Metastases: Conventional to Stereotactic Body Radiation Therapy. <i>Seminars in Radiation Oncology</i> , 2023, 33, 172-180.	1.0	2
1132	Radiation Therapy at the End-of-Life: Quality of Life and Financial Toxicity Considerations. <i>Seminars in Radiation Oncology</i> , 2023, 33, 203-210.	1.0	2
1133	Follow-Up Imaging Guidelines for Patients with Stage III Unresectable NSCLC: Recommendations Based on the PACIFIC Trial. <i>Current Oncology</i> , 2023, 30, 3817-3828.	0.9	0
1134	Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Current Medical Science</i> , 0, , .	0.7	0
1135	Stereotactic Magnetic Resonance-Guided Adaptive and Non-Adaptive Radiotherapy on Combination MR-Linear Accelerators: Current Practice and Future Directions. <i>Cancers</i> , 2023, 15, 2081.	1.7	5
1136	The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer. <i>Surgical Oncology Clinics of North America</i> , 2023, , .	0.6	0
1137	Long-term characterization of MRI-morphologic alterations after active motion-compensated liver SBRT: a multi-institutional pooled analysis. <i>Acta OncolÃ³gica</i> , 2023, 62, 281-289.	0.8	0
1138	Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?. <i>Current Urology Reports</i> , 0, , .	1.0	0
1139	Outcomes of solitary postoperative recurrence of esophageal squamous cell carcinoma diagnosed with FDG-PET/CT and treated with definitive radiation therapy. <i>Esophagus</i> , 0, , .	1.0	0
1140	Radiotherapy in Oligometastatic and Oligoprogressive Disease. <i>The Journal of Tepecik Education and Research Hospital</i> , 2023, 33, 1-6.	0.2	0
1141	Repeat stereotactic body radiotherapy for oligometastatic disease. <i>Radiotherapy and Oncology</i> , 2023, 184, 109671.	0.3	1
1142	Description and efficacy of a responseâ€based â€œ<sc>QUAD</sc>â€-cyclical hypofractionated palliativeâ€intent radiation protocol in dogs with macroscopic solid tumours: 108 cases. <i>Veterinary and Comparative Oncology</i> , 2023, 21, 378-390.	0.8	0

#	ARTICLE	IF	CITATIONS
1143	Intra-fraction motion of pelvic oligometastases and feasibility of PTV margin reduction using MRI guided adaptive radiotherapy. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
1144	Stereotactic body radiotherapy for mediastinal lymph node with CyberKnife®: Efficacy and toxicity. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2023, , .	0.6	0
1145	Endobronchially Implanted Real-Time Electromagnetic Transponder Beacon®-Guided, Respiratory-Gated SABR for Moving Lung Tumors: A Prospective Phase 1/2 Cohort Study. <i>Advances in Radiation Oncology</i> , 2023, 8, 101243.	0.6	0
1146	Magnetic resonance-guided stereotactic body radiation therapy (MRgSBRT) for oligometastatic patients: a single-center experience. <i>Radiologia Medica</i> , 2023, 128, 619-627.	4.7	1
1152	Opportunities and challenges of low-dose radiation to enable immunotherapy efficacy. <i>International Review of Cell and Molecular Biology</i> , 2023, , .	1.6	0
1178	Models of multidisciplinary management. , 2024, , 39-44.		0
1180	Considerations involving reirradiation. , 2024, , 127-140.		0
1181	Palliative radiotherapy in oligometastases. , 2024, , 263-274.		0
1182	Palliative radiotherapy in bones. , 2024, , 223-230.		0
1184	Palliative radiotherapy in the spine. , 2024, , 249-262.		0
1185	Palliative radiotherapy in the breast and chest wall. , 2024, , 163-172.		0
1186	Palliative radiotherapy in the older adult. , 2024, , 275-288.		0
1195	Radioonkologische Techniken in der Tumorbehandlung: Protonen/Schwerionen, Tomotherapie, SRS/SBRT, MR-Linac. <i>Springer Reference Medizin</i> , 2023, , 1-4.	0.0	0
1212	Extracranial Oligometastases. , 2023, , 265-277.		0
1213	Lung. , 2023, , 137-159.		0
1236	Radiation Therapy for Metastatic Liver Cancer. , 2023, , 1-11.		0
1243	Future of SBRT with Photon and Charged Particles. , 2023, , 311-322.		0
1245	Other Indications. , 2023, , 215-230.		0

#	ARTICLE	IF	CITATIONS
1246	Oligomets. , 2023, , 199-214.		0
1247	Introduction and History of Stereotactic Body Radiation Therapy (SBRT). , 2023, , 3-10.		0
1260	When and How Should Radiotherapy Be Considered for Pain Management?. , 2023, , 68-77.		0
1261	Radiation Therapy for Pancreatic Cancer: Current and Evolving Paradigms. , 2023, , 37-55.		0
1262	Nasopharyngeal Carcinoma in Pediatric and Adolescent Patients. Medical Radiology, 2023, , .	0.0	0
1303	Deep learning for medical image segmentation. , 2024, , 107-135.		0
1333	Clinical Applications of MR-Linac in Oligometastatic Disease. , 2024, , 217-242.		0